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ABSTRACT
Spinal Cord Injury (SCI) is a debilitating condition which causes neurological
damage and can result in paralysis. SCI results in immediate mechanical damage to the
spinal cord, but secondary injuries due to inflammation, oxidative damage, and activated
biochemical pathways leading to apoptosis exacerbate the injury. The only currently
available treatment, methylprednisolone, is controversial because there is no convincing
data to support its therapeutic efficacy for SCI treatment 1. Because of its inability to
show marked improvement in SCI patients, methylprednisolone does not have approval
from the FDA, and remains classified as an optional treatment for SCI. In the absence of
an effective SCI treatment option, 17β-estradiol has gained significant attention for its
anti-oxidant, anti-inflammatory, and anti-apoptotic abilities, all events associated with
secondary SCI. When applied to SCI animal models for treatment, significant functional
recovery has been reported. Sadly, estradiol is prothrombotic and leads to
thromboembolic events which are exacerbated in the individuals with SCI due to their
lack of mobility. This effect has been shown clinically in adult males taking high dose
estrogens for prostate cancer treatment 2. However, thromboembolism has not been
reported when low estrogen doses are used for treatment. These systemic adverse effects
preclude the use of free estrogen even for local administration due to short drug half-life
in the body.
Biodegradable nanoparticles can be used to increase half-life after local
administration and to bestow sustained release. Sustained release using PEGylated
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biodegradable polymeric nanoparticles constructed from poly(lactic-co-glycolic acid)
(PLGA) will endow a consistent, low, but effective dose to be delivered locally. This will
limit systemic effects due to local administration and low dose, sustained release. PLGA
was chosen because it has been used extensively for sustained release, and has a record of
safety in humans 3. Hydrophilic polymers can be attached to the carrier to limit protein
adsorption and prevent uptake by the reticuloendothelial system (RES) or immune system
4-6

.
Here, we propose to develop PEGylated nanoparticles loaded with 17β-estradiol

for treatment of secondary SCI. We will formulate biodegradable poly (lactic-coglycolic) acid (PLGA) nanoparticles surface modified with PEG groups to prevent uptake
and to provide sustained release of the drug at the injury site. We will evaluate the
performance of the nanoparticle and determine the best dosage for effective treatment of
SCI. Our ultimate hypothesis is that local administration and sustained release of the drug
endowed by the nanocarrier will enhance treatment efficacy. The main goal is to
characterize the nanoparticle delivery system in vitro and in appropriate cell models to
determine the range of effective doses for application to an animal model.
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CHAPTER ONE
INTRODUCTION
This document describes the graduate work in the department of Bioengineering
at Clemson University for the past four years which has focused on nanomaterials and
their application to solve medical problems. The research aim has been to use
nanotechnology, specifically surface modified nanoparticles and liposomes, to carry
pharmaceuticals which suffer from rapid clearance and adverse side effects, and release
them in low, therapeutically relevant levels only at the site where they are needed.
Specifically, this work focuses on the application of nanobiotechnology for the
treatment of spinal cord injury to prevent secondary damage which follows the primary
insult. To best treat this disease, the researchers endeavored to develop a drug delivery
system that could be administered locally and release a slow, consistent dose of an
estrogenic drug to the injured tissue. To achieve this goal of local, sustained drug release
biodegradable nanoparticles were used which were constructed from biocompatible, FDA
approved polymers.
The second chapter of this document includes a detailed review of the relevant
literature to supply the reader with an understanding of the foundation upon which this
work is built. This includes a discussion of spinal cord injury and the events that
accompany and cause much of the damage associated with this type of injury. The third
chapter discusses the innovation and significance of the work and discusses the specific
aims which were developed to evaluate the proposed treatment.
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The formulation development and characterization of the nanoparticle delivery
system is described in chapter four. This includes a discussion of the experiments
designed to determine the loading efficiency of the estrogenic drug into the polymeric
particle, analyze different poly (ethylene glycol) (PEG) contents to maximize this loading
efficiency, and the evaluation of the size and stability of the formulation. This chapter
also includes an in vitro release method to analyze the release of hydrophobic small
molecule drugs. This method utilizes albumin, a ubiquitous protein in the bloodstream,
whose function is the transport of such molecules. In using the protein as an active
transport system in a dialysis based filtering system, the release profile is more closely
related to that which would be seen in the body because the same protein transport
system is present in both cases. The details describing this method and the possible
applications are outlined in the chapter.
The first in vitro cell culture model used to evaluate the efficacy of the developed
nanoparticle drug delivery system is described in chapter five. This includes the
experiments necessary to determine the neuroprotective effect of 17β-Estradiol in a
neuroblastoma model. This is done by quantifying the viability of cells protected by
estrogen in induced injury-like events. Here, the author illustrates that the treatment
effectively protects the neuroblastoma cells and that the nanoparticle delivery system is
an improvement for delivery over DMSO for in vitro cell culture models. Also shown is a
dose dependence study to determine which dose most effectively protects cells. Also
evaluated is the best pre-treatment time for effective treatment. The biodegradable
nanoparticle system will have a lag time before there is release because the drug is
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released as the particle degrades. The neuroblastoma cell model is limited in its ability to
provide dosage information that is translatable to an in vivo animal study because it is a
cancer cell line. This means that it is more resilient than many nervous system cells, and
the studies described herein show that it was not as responsive to estrogens as was
expected. This led to the exploration of a primary cell model that would be a more
effective model to translate this treatment into animal models.
The sixth chapter describes the primary model used to evaluate the estrogen
delivery system. Dorsal Root Ganglion neurons were harvested from chicken embryos
and challenged by SCI-like events. Treatment groups were exposed to estrogen delivered
by the nanoparticle formulation to determine dose dependence in a similar manner to that
done for the neuroblastoma cell line. Pre-treatment time was also performed as was done
for the neuroblastoma model. This model dictates the doses and pre-treatment times that
will be used to start the animal studies to evaluate the drug efficacy.
Overall conclusions of the studies and an examination of the potential future work
related to this work are included in chapter seven. First, the implications and possible
applications of the work are summarized. Second, there is a discussion of work to be
done to carry this technology towards practical applications. The application of the
described technology to treat those who suffer from spinal cord injury is the major goal
of this project and the first few steps taken to reach this goal are summarized herein.
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CHAPTER TWO
LITERATURE REVIEW
There is a large emphasis on healthcare and improving the quality of life in the
United States. The amount of money spent on healthcare soared to 17.3% of the Gross
Domestic Product, or 2.5 trillion dollars, in 2009 and continues to the rise according to
USA Today 7. According to the same article, 246 billion dollars of this total was spent on
prescription drugs. These Figures illustrate the demand for modern healthcare which is
largely met by the development of effective pharmaceuticals.
However, many of these pharmaceuticals have limitations. One major limitation
of many drugs is a low circulation time, which is one of the causes of low drug
concentrations at the disease site 8,9 Often, high doses are given to achieve high enough
concentrations at the disease site. Despite these high doses, only a fraction of the drug
arrives at the desired location and low concentration of drug at a diseased site prevents
high levels of efficacy 10. In addition, side effects plague many patients, cancer
chemotherapeutic drugs are one notable example, and high doses only aggravate this
problem 11, 12.
This limited circulation time and low therapeutic concentrations at the disease site
occur because the human body is effective at removing foreign molecules, including
drugs, which results in a short time for the drug to perform its therapeutic action. Most
therapeutics that utilize the circulatory system for drug delivery see the vast majority of
the drug cleared from the body in just a few hours 8. These are just a few of the
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limitations of modern medications, others exist, many of which are specific to each
individual drug.
The limitations listed can be addressed, to a certain degree, by the modern
advances of nanotechnology 13, 14. Nanotechnology has gained global attention for its
unique ability to hurdle some of the barriers that have limited application and innovation
of many potentially effective therapeutics. The application of nanotechnology to drug
delivery has seen dramatic success in this area. As will be discussed in this review,
liposomes and nanoparticles as drug delivery systems have answered many of the
common drug limitations. Some of the earliest nanomedicine research was dedicated to
delivering small molecules to a target site with as much specificity and as long a
circulation lifetime as possible 4, 5, 15. A renewed excitement for drug delivery by
liposomes and nanoparticles was seen in the past two decades as a formulation for each
has achieved FDA approval 16-21. A barrage of research to improve these approved
delivery devices began and still continues with attempts to actively target and increase
efficacy 22, 23.
There has been a significant amount of research done on liposomes and
nanoparticles as pharmaceutical carriers for a variety of small molecule and protein
drugs. Small molecules, proteins, and enzymes have been used both as targeting moieties
and for their therapeutic potential 24-28. High specificity and rapid reaction rates make
proteins and enzymes excellent candidates for therapeutic treatment, but some limitations
exist 29-31. Many of these limitations can be addressed by a nanotechnology based
delivery system that has been thoroughly characterized and evaluated for efficacy with
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minimal toxicity and side effects. Such a system can provide a medium for delivery,
stabilization of the drugs, and enable site specific accumulation of drugs. All of which
make for a more effective treatment. Overcoming these limitations to effective medical
treatment could increase the development of new treatments and improve the efficacy of
existing therapies. In addressing these barriers, nanomedicines have the potential to
revolutionize the pharmaceutical industry and improve healthcare worldwide.
2.1.

Spinal Cord Injury
Spinal cord injury is a debilitating condition for many which causes neurological

damage and can result in paralysis. There are an estimated 265,000 people are living in
the United States with SCI in 2010, with approximately 12,000 new cases each year 32.
The main causes of spinal cord injury are illustrated in Figure 1. The estimated lifetime
costs for individuals of age 25 and 50 when afflicted with SCI are $1,461,255 and
$1,031,394, respectively, for incomplete motor function loss at any level. The risk and
cost escalates as the severity of injury increases.

Figure 1: Breakdown of the etiology of spinal cord injuries since 2005 32
6

2.1.1. Primary Injury
The primary injury originates with a mechanical insult. Common causes for a
mechanical insult with enough force to cause physical disruption of the spinal cord are
shown in Figure 1. Immediately, there is damage to the structural components of the
spinal cord (Figure 2), as well as damage to the vasculature and to the spinal cord cell
population 33. Axonal disruption also occurs upon the mechanical insult and often
hemorrhage follows the injury. Despite the extensive damage that can be caused by
primary injury, because of the unpredictable nature of such injuries, there is little that can
be done to prevent these injuries. However, secondary effects which follow the primary
injury can lead to exacerbation of injury and further motor loss can potentially be treated
34, 35

.

Figure 2: Graphical representation of a spinal cord injury36
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2.1.2. Secondary Events
Secondary damage is of primary concern here because much of the neurological
damage in SCI is caused after the initial trauma or primary insult. This secondary injury
involves many different harmful pathways including a local inflammatory response,

Table 1: A comparison and contrast between primary and secondary injury

PRIMARY INJURY

SECONDARY INJURY
Occurs after the initial injury, and is

Occurs upon mechanical insult
mediated by biochemical events after
which initiates the injury.
primary injury
Caused by a several different factors
Cell death and local damage caused

induced at the injury site, but is caused by

by localized mechanical force.

signals and reactions, instead of
mechanical force.
Drugs can be used to prevent or alleviate

No treatments to prevent this type of
the effects of events which cause exacerbate
damage, only to promote healing.
SCI
Secondary injury is treatable and some of
Not preventable and cannot be
the resulting damage can be diminished or
treated prior to injury
prevented
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production of free radicals and reactive oxygen species (ROS),ischemia/reperfusion,
glutamate excitotoxicity, ionic changes, and the activation of pro-apoptotic proteases 37.
At least a few of these pathways are linked in etiology. In order to understand the best
treatment methods for this condition, it is vital to understand the damaging pathways
which lead to neurological damage and potential paralysis.
After the primary spinal cord injury, migration of neutrophils and macrophages
(or microglia, as macrophages are called in the central nervous system (CNS)) to the
damaged site occurs 38. These cells are characteristic of inflammation and are
instrumental in the local cleanup necessitated by the injury. However, these cells release
ROS that cause oxidative damage in the local tissue 38. In addition, ischemia and
reperfusion also increase local free radical concentrations which cause oxidative damage
and exacerbate the injury 39.
Another deleterious pathway begins with the up-regulation of an amino acid
signaling molecule, glutamate, during secondary SCI events 40. Glutamate receptors on
the surface of neuronal cells regulate the intracellular ionic balance. NMDA receptor is a
specific glutamate receptor which responds to glutamate as well as to its namesake, Nmethyl-D-aspartate (NMDA). This receptor has been incriminated in the pathology of
secondary SCI because it activates pathways directly involved in apoptotic cell death 40.
NMDA receptors, and some other glutamate receptors, regulate calcium ion ([Ca2+])
influx into the nervous system cells. An increase in intracellular [Ca2+] is also potentially
mediated by mitochondrial damage caused by SCI which affects the activity Na+-K+

9

Figure 3: The biochemical progression of secondary injury following the
primary insult which initiates the cascade of events.

10

ATPase leading to imbalance in Na+-Ca2+ exchange 41. This rise in [Ca2+] leads to
protease activation, among activation of other deleterious pathways. Calpain is a calcium
dependent protease activated in this process. Calpain is always present and plays a role,
but in higher concentrations, as is seen in secondary SCI due to the local biochemical
dysfunction, it can initiate a pathway fatal to nervous system cells by degrading
cytoskeletal and membrane proteins 42. The proteolytic activity performed disturbs the
local environment and leads to apoptosis of CNS cells 42. Calpain is an upstream
regulator of Bax and Caspase-3, both which are implicated in apoptotic cell death. Thus,
it is vital for a potential therapeutic to have the ability to regulate the response initiated by
glutamate if a therapy is to be effective in treating secondary SCI.
2.1.3. Timing of Spinal Cord Injury Events
The timing of these events following SCI is critical to the development of an
effective treatment and is outlined by Norenberg et al43. Immediately after injury for the
first 1-2 hours there is little sign of secondary events except for some change in the
vasculature. Swelling, hemorrhage, and inflammation follow in the acute phase of injury.
Swelling is present from approximately 3 hours to 3 days after the injury. Inflammation
also occurs with neutrophils invading the site at about one day, reaching a maximum at 2
days and retreating almost completely by 3 days. Some hemorrhaging occurs alongside
these events, but is usually not significant in a typical SCI. Neuronal cells are particularly
susceptible to death by necrosis or apoptosis in the first few days following injury, and
demyelination is characteristic during this time period as well. The intermediate stage
follows from a few days to several weeks. This stage is characterized by revascularization
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of the injury site and microglia present in the site working to clean up the injury site. Late
phase healing results in scar formation and final remodeling of the injury site. Because
the acute stage is pivotal in the healing process and there are many positive and negative
events that can occur during this stage, the first few days are critical for surgical
intervention and treatment with a few weeks after injury still seeing many of the
secondary effects taking their toll at the injury site.
We would then expect secondary events to play a role in preventing the recovery,
or even decrease the neurological state of an individual with a SCI. A study by Gorio et al
showed that there was essentially no neurological recovery for 72 hours in a rat model
treated with saline. The rats started with an average mean motor score of 1.2 (on a rating
scale of 1-7, increasing as motor skills improved), which decreased in the first 12 hours

Figure 4: Methylprednisolone is the current standard of care for SCI
patients. It resembles Prednisone in chemical structure.
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and showed almost no recovery up to 72 hours44. There have been many studies that have
shown that intervention within 72 hours has shown a significant increase in functional
recovery 45. This indicates again that immediate treatment to alleviate secondary injury is
vital to achieve the highest level of neurological recovery.
2.2.

Current Treatments for Spinal Cord Injury
The current treatment for individuals with SCI is Methylprednisolone (MP). MP

is a glucocorticoid similar to prednisone in structure. The use of MP is very controversial
because a contingency of experts consider its therapeutic effects to be questionable at
best 41. Many physicians regard MP as a drug with insufficient proof of its efficacy as a
SCI therapy 1. These opinions are based on clinical results from three studies performed
in the National Acute Spinal Cord Injury Study (NASCIS) which did not show an
improvement in the primary outcome of patients treated with MP 46-48. As a result, MP is
concluded to be “an inappropriate standard of care” by Hurlbert and many other
physicians 1, 49.
The referenced NASCIS I, II, and III results did not show improvement in the
primary outcome, but a post-hoc analysis determined that early administration (eight
hours after injury or before) resulted in a functional improvement. Based on this analysis,
MP quickly became a popularly used treatment for SCI. Since the adoption of MP for
SCI treatment as a standard of care, the post hoc analysis performed on the NASCIS data
has come under considerable fire for statistical analysis, randomization, and clinical end
points 46,50-52. Another critical review of the analysis notes that the placebo control group
treated before 8 hours did not do well, not only when evaluated against the MP treated,
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but also against the post 8 hour placebo 53. This indicates that there may have been a
problem with the control group, which could dramatically improve the statistical
significance of the clinical study. Thus, for some reasons mentioned here along with
others not mentioned (see relevant literature 1, 41, 49, 52, 53), there is considerable
controversy around the use of MP for treatment of SCI. The present study is designed to
present a novel, delivered therapeutic to effectively treat SCI.
There are several other treatment methods that are being explored for their
neuroprotective abilities in the absence of a strong treatment option. One potential
treatment option is minocycline, an antibiotic that also has shown some success against
secondary events such as inflammation and apoptosis. Another experimental treatment
option is fullerenols, which are carbon based nanostructures which act as free radical
scavengers and interact with glutamate receptors and impart a similar neuroprotective
affect to estrogens 54. There are many other therapies that have also been investigated
including bone marrow stromal cells, erythropoietin, and glutamate receptor antagonists
involved in the pathology of SCI55, 56.
Several groups who published animal studies using minocycline as a
neuroprotectant in traumatic SCI did show that locomotion scores (BBB method) did
improve under the therapy 57, 58. A study initiated by the NIH to verify the result of these
studies was unable to replicate the level of success achieved previously 59. The results of
a phase II clinical trial into minocycline for spinal cord injury treatment were published
earlier this year and indicated no significant difference between the treated and a placebo
60

. There was an indication that there was a therapeutic effect, but significance was not
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reached for any group. Overall improvement was slightly higher than the placebo, but,
again, was not significant.
Erythropoietin is a cytokine that is involved heavily in the erythrocyte life cycle.
It has also been shown to be involved in the development of the nervous system 61. After
SCI, it is released in response, at least in part, to hypoxic conditions and prevents
apoptosis and inflammation. It has been examined in SCI animal models as a potential
treatment and has seen success 61, 62. However, there remain concerns due to an increased
risk of thrombosis after repeated treatments 63.
The major downside to most new treatments, such as fullerenols, is that they are
unknown and have not been thoroughly evaluated for safety. This lack of approval
necessitates extensive clinical trials to prove safety and efficacy. Few treatment options
have been explored as extensively as estrogens for treatment of SCI and estrogens have
the distinct advantage of having already been approved in many different forms (i.e. birth
control, menopausal relief treatment options). Some of these forms of estrogens have
been used for over 60 years and are familiar drugs which have already attained approval.
In addition they have shown the ability to effectively alleviate many of the secondary
injury events following SCI.
2.3.

Estrogens for Treatment of Spinal Cord Injury
As illustrated herein, there are many deleterious pathways involved in the

pathology of SCI. For this reason, it may be necessary to use several treatments to
effectively treat SCI, or use a single treatment which plays multiple therapeutic roles 37.
One promising candidate as a multi-acting agent against SCI is 17β-estradiol. This
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Figure 5: 17β-Estradiol is a hormone that is capable of playing several roles
in the therapy of SCI.
estrogen is a steroid hormone that has been studied extensively for its therapeutic
potential, much of which is not due to its estrogenic properties 64. 17β-estradiol has been
shown to have a threefold effect when used in SCI. First, it has been shown to be a potent
anti-oxidant, thus alleviating the oxidative stress brought on by inflammation,
ischemia/reperfusion, and the accompanying ROS 64. Second, this estrogen has exhibited
anti-inflammatory activity. This anti-inflammatory action is not anti-oxidant in nature,
but inhibits microglial activation at the injury site and limits the release of cytokines,
ROS, free radicals, and complement proteins 65. Finally, and perhaps most importantly,
17β-estradiol is anti-apoptotic. As mentioned previously, SCI initiates many pathways
which can lead to apoptosis. This estrogen inhibits glutamate induced apoptosis indicated
previously 40, 41. This estrogen has also seen success when applied to in vivo models for
experimentation 34, 37, 66
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Despite the success seen in these experiments, there is concern for use of high
concentrations of the estrogen due to clinical results which indicated that it is
prothrombotic 67. Clinical results of estrogens used to treat men with prostate cancer have
shown increased risk of thromboembolism. This is especially dangerous for individuals
with limited mobility because clots can form and more easily block circulation in lower
extremities. If used in high doses or administered systemically, 17β-estradiol could cause
this side effect, which could be especially deleterious68,34. There is also some concern
due to possible carcinogenicity associated with high concentrations 67, 69. More minor side
effects have also been reported and could be problematic for population of SCI patients
which is largely male70. For this reason, there have been experiments performed to test
the efficacy of the estrogen when used in physiological low doses, which have resulted in
limited side effects in clinical studies 34, 41. These studies have seen success in animal
models with SCI, but further studies are warranted in an effort to increase local drug
concentration while restricting systemic availability to limit potential side effects of the
treatment.
2.4.

Nanotechnology for Drug Delivery
Nanoparticles are nanoscale spheres capable of carrying drug loaded into the bulk

or loaded onto the surface. Nanoparticles can be polymeric, metallic, or ceramic but are
most commonly polymeric in the case of sustained release drug delivery by a
biodegradable particle. PLGA is a common polymer that degrades by hydrolysis in the
body. This degradation, in tandem with its biocompatibility, has made it a popular
polymer for controlled release of drugs. Research on controlled drug delivery has
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experienced profound expansion since the first controlled release study done by Dr.
Folkman at Harvard in 1964 71. Research in the area of controlled release has advanced
from patches to microparticles and now it merges with the field of nanotechnology to
attempt to revolutionize medicine once more 72. The ability to control the release of
incorporated drugs is appealing for many pharmaceutical applications because high doses
can lead to side effects. These high doses are no longer necessary because of modern
innovations in sustained release of drugs. Intravenous administration of such degradable
particles is beginning to see application, but local administration is more fitting with the
current technological abilities of these particles for controlled release of therapeutic
drugs.
There are many diseases which have drastic potential to see improved outcomes
with the application of nano-sized drug delivery devices as a treatment modality.
Sustained drug release is very useful in drug delivery, but often there is a need for
localization of the particles when the location of the diseased site is unknown or
inaccessible. Targeting these particles to this site has the potential to effectively treat
many diseases including cancer. A brief look into the pathology of cancer can illustrate
the utility of nanoscale drug delivery not only to cancer patients, but to a wide variety of
disease states which see some similar physiological pathologies.
Current cancer chemotherapy agents have been shown to be cytotoxic and have
many side effects in vivo. These side effects include some more familiar symptoms like
hair loss, nausea, as well as more hazardous pathologies such as neutropenia and kidney
failure 22. This inherent cytotoxicity limits the doses of these therapeutic drugs that can be
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administered to patients. This systemic cytotoxicity is caused by the drug acting on all
cells in the body, not just the on cancer cells. Even if new chemotherapy agents could be
identified, there are still the overarching issues of systemic toxicity, high doses, and drug
resistance that can build up over time. Thus, if a carrier could be designed that would
deliver the drug only to the cancer site it would severely limit the action of the cytotoxic
drug on healthy tissue and restrict its action to the cancer cells. This directed delivery is
often called ‘targeting’ and may provide effective solutions for the major hurdles in
oncology. Overcoming these barriers is the chief goal of oncologic nanomedicine. The
ability to design these targeted nanocarriers is a distinct advantage of nanotechnology
which allows consistent low drug doses to be delivered to the targeted site.
Many the physiological conditions present in cancer which make it a good
candidate for drug delivery are also present in many diseases. The immediate response to
a diseased state is for the immune system to attack it. The immune system response
beyond the first line of defense in the local tissue macrophages is the delivery of other
lymphocytes via the blood stream. Inflammation and swelling present in many disease
states cause higher levels of local blood flow and a leaky vasculature to accommodate the
increased response to the disease. This allows the for passive targeting and active
targeting which can lead to accumulation of the therapeutic at the diseased site. Specific
biomarkers are also present in many disease states and can be used to actively target the
drug delivery system to the necessary location. However, an analysis should be
performed to determine whether a local or systemic administration will result in better
treatment efficacy.
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2.4.2

Nanoscale Delivery Vehicles
2.4.2.1.

Nanoparticles

Nanoparticles are nanoscale spheres capable of carrying drug loaded into the bulk
or loaded onto the surface. Nanoparticles can be polymeric, metallic, or ceramic but are
most commonly polymeric in the case of controlled release drug delivery by a
biodegradable particle. Metallic particles have been studied for their unique properties as
well.

Figure 6: A simple diagram illustrating a common method of protein
immobilization on a nanoparticles surface is shown on the left. A
chloromethyl reactive group is attached to the surface of the nanoparticle
and this group reacts with amine groups on the surface of the protein
resulting in conjugating. 73
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Gold nanoparticles are the earliest nanoparticles, and have been studied for a variety of
applications. Iron oxide nanoparticles are of interest because they can act as magnetic
resonance imaging (MRI) contrast agents and, as we will mention later, have gained
much attention in the area of hyperthermic cancer treatment.

Figure 7: An image of a nanoparticle taken with a transmission electron
microscope (TEM) 74.
2.4.1.2.

Liposomes

Nanoparticles constructed from lipids that form bilayer micelles are called
liposomes and have a unique set of properties that makes them ideal for certain delivery
applications. Liposomes are made up of lipids which have a structure that mimics the cell
membrane, but lack the numerous embedded proteins present in cell membranes. The
properties of the liposomes depend on their lipid composition. Liposomes can be
unilamellar (single membrane layer) or multilamellar (multiple membrane layers), but the
latter are rarely employed for biomedical applications. Liposomes were first proposed as
drug delivery devices in 1974 by Gregoriadis et al. 75, and have since gone through many
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changes to bring liposome technology where it is today. All liposomes contain
cholesterol which provides fluidity to the membrane just as it does in the cell membrane.
As new breakthroughs have shown how these carriers can be effective, it became
necessary to add other components to liposomes to increase their ability to reach the
therapeutic site. Amphiphilic molecules with polyethylene glycol 4 chains on the end
were used to limit opsonization in the body and increase circulation half-life. There has
also been attachment of certain targeting moieties 76 to liposomes to facilitate
incorporation into malignant cells at the therapeutic site.
Site specific delivery and controlled release are the main two goals for
nanoparticles and liposomes as nanotherapeutics. Figure 3 illustrates the evolution

Figure 8: The evolution of liposome as drug carriers is illustrated here in an
image by Torchilin. Image A on the left shows the original liposomal carrier
with two different drug types able to be loaded into the liposome.
of liposomes as drug carriers. (a) Represents a hydrophilic drug loaded into the interior
of the liposome in a water soluble phase and (b) represents a lipophilic drug loaded into
the hydrophobic liposomal wall. Later, as pictured in B, antibodies were attached to
liposomes as targeting moieties by direct attachment (c) or using small linker molecules
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(d). C represents the polyethylene glycol spacers developed for increased circulation time
due to opsonization resistance (opsonin molecule (f) is repelled by PEG spacers). D
shows the combination of previous advances with (g) being an antibody directly attached
to the surface or the more effective design (h) with the antibody attached to the distal end
of the PEG spacer. The most advanced liposome pictured in E illustrates the complex
capabilities of modern liposomes with the combination of a PEG spacer (I), a distally
modified spacer with a targeting moiety (j), a molecule involved in biorecognition for
diagnostic purposes. Other possibilities include cationic lipids (l) for DNA (m)
complexation, incorporation of stimuli-sensitive lipids (n), stimuli sensitive spacers (o),
attachment of cell penetrating moieties (p), involvement of viral components (q), loading
of magnetic nanoparticles (r) for imaging, and colloidal gold or silver nanoparticles (s)
for electron microscopy.76
2.4.2. Effects of Size
The size of these nanoparticles is of the utmost importance. Particles under 1
micron are necessary to increase the surface contact to the external system which allows
increased loading in the case of surface attachment 77. It is also imperative to have
nanoparticles that are able to travel through capillaries which are as small as several
microns. This demand has resulted in the explosion in the field of nanotechnology. The
biodistribution of liposomes, or where they find their final resting place in the body, is a
factor of the size 77. Smaller particles are cleared from the body within minutes by the
kidneys. Many larger particles are taken up by the reticuloendothelial System (RES)
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which is made up of tissue macrophages such as liver macrophages, called Kupffer cells,
and spleen macrophages.
The ability of a delivered drug to reach a tissue is dependent on the fenestration of
the epithelial lining of the blood vessels. There must be a high fenestration size in the
epithelial lining to allow nanoparticles into the interstitial space 78. This high fenestration
size occurs when vessels become leaky to allow more nutrients into the interstitial space
which happens in damaged tissue, as illustrated in Figure 2. Leaky vessels are common in
cancerous regions as well as at an inflammation site. In normal, healthy tissues, the drug
can still reach the interstitial space and exert its pharmacological action, but only when
the free drug is able to move across the vessel lining. This occurs much less often in
controlled release carriers as compared to a simple injection of free drug. There are
studies that have measured the different fenestration sizes of organs in different animals
and there appears to be some consistency in the fenestration size of different diseased
organs 78, 79. This could provide some guidelines to researchers attempting to target a
specific organ by using nanoparticles designed with a size and targeting moiety for that
diseased organ.
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Figure 9: This Figure illustrates the role that fenestrated epithelium
(leaky vessels) play in drug delivery. Some drug is able to penetrate the
continuous vascular endothelium, but drug in a carrier is not. This limits
systemic exposure of tissues to the drug and isolates the drug location and
action. This is particularly true of cancer treatment regimes which utilize
local fenestrated epithelium as a means to increase local concentration and
efficacy. 77
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2.4.3. PEGylated Liposomes and Nanoparticles
A major breakthrough in liposome and nanoparticle technology was made when
polyethylene glycol was chemically attached to the particle surface. The human body is
adept at removing foreign objects to prevent invasion of pathogens. When any foreign
object enters the body, it is immediately coated by proteins (opsonized) that mark it for
uptake by natural killer cells. This process occurs when nanoparticles or liposomes are
introduced into circulation limiting their half-life in blood stream to several minutes.
Thus, it becomes important for any drug carrier to be resistant to opsonization.
Hydrophobic surfaces are more prone to protein adsorption and are therefore undesirable
on drug carriers. This becomes a problem for particles with hydrophobic surfaces, and

Figure 10: Graphical representation of a nanoparticle that has been surface
modified with poly(ethylene glycol) (PEG). (Credit: Olga Reukova and
Vladimir Reukov)
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results in their rapid removal from the blood stream. Thus, the challenge to develop a
protein-resistant coating for hydrophobic particles to prevent rapid clearance was
presented. This call was answered by researchers Alexander Klibanov and Vladimir
Torchilin 4, and several other groups simultaneously 80, 81, who applied a principle for
surface coating that had been developed at Rutgers in the 1960’s 5. It was applied to
nanoparticles a few years later by a group82 out of Massachusetts Institute for Technology
(MIT) headed by Robert Langer 83. This technology utilizes a polyethylene glycol (PEG)
polymer chain attached to the surface of the liposome. This PEG chain is extremely
hydrophilic and can prevent protein adsorption. A lack of opsonization limits the immune
systems rapid recognition and uptake of the PEGylated nanocarriers resulting in a longer
circulation time or increased residence time in the tissue once it has vacated the
vasculature. Otherhydrophilic spacers, such as poly (hydroxylethyl methacrylate)
(polyHEMA) have been applied to nanoparticle systems with similar success.
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Figure 11: Pisani et al show an ability to finely tune the size of microparticles
constructed from PLGA-PEG polymers. The images proceed from top to bottom
with increasing copylymer concentrations (0, 5, 10, 20, 40, 50, 60, 80, 90 and 100%
PLGA PEG). As the copolymer concentration increases there is a more pronounced
‘hairy’ texture to the corona of the particles. This increase is due to PEG interacting
with the aqueous environment preferentially over the polymer core. This creates a
solvent sphere around the particle. The images include the left column (bright field),
the middle column (confocal microscopy), and the right column (SEM) 84.
2.4.5. Methods of Nanoparticle Targeting
2.4.4.1.

Passive Targeting

Earlier in this review, the leaky vessels present in malignant tumors and other
damaged tissues were referenced. These leaky vessels are the result of fenestrated
epithelium and pressure gradients between the vessels and the interstitium. This leakiness
causes an increased flow to the cancerous site which results in an accumulation of
nanoparticles being transported in the blood 85. Due to the rapid production of tissue
vasculature at malignant sites, there is an inadequate lymphatic system presence which
results in further accumulation due to lack of drainage. This is where PEGylated particles
have a comparative advantage because of their extended circulation time 85. The outcome
of which is a relatively high concentration of engineering particles at the cancer site
compared to normal, healthy tissues. This effect has been aptly named the enhanced
permeation and retention effect (EPR) by the researcher who first described it in 2001 86.
Maeda also noted that there was a higher concentration of the particles in the tumor
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tissues than the plasma. The EPR effect resulted in a very popular method of liposome
delivery due to its convenience as well as it highly effective nature. This method of
delivery has been called passive targeting or passive diffusion.
There are two nanoparticle formulations approved by the United Stated Food and
Drug Administration (FDA) that are designed to carry small molecule cancer treatments
by passive diffusion with several more currently in clinical trials. The first nanoparticle to
be FDA approved is called Doxil and is a liposomal formulation for the treatment of
cancer. Doxil first received approval in 1995 for cancer treatment and received full
approval after a several years in accelerated approval in 2003. Doxil is now approved for
treatment of several types of cancer 87, 88. A discussion on Doxil and the related research
is contained in the section on controlled release later in this review. The second, titled
Abraxane, is a nanoparticle built from the protein albumin and was approved in 2005 89,
90

. Abraxane is also discussed in more detail later is this review when discussing

approved therapies utilizing controlled release.
2.4.4.2.

Active Targeting

A different class of nanocarriers utilizes highly specific interactions of
biorecognition molecules (“targeting ligands”) with specific biomarkers to achieve drug
delivery to a tumor or other location in the body. This therapeutic methodology is
referred to as ‘active’ targeting. This approach heavily utilizes proteins as the most
natural targeting ligands, especially those proteins which are already involved in
signaling and cell recognition.
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The most common protein targeting agents used in active targeting are IgG
antibodies immobilized on the nanoparticle surface. These immune system proteins have
a very high specificity and can selectively and effectively localize the nanocarrier at the
site of therapeutic need. When antibodies are immobilized on liposome surfaces for
targeting the resulting constructs are aptly named ‘immunoliposomes’. Immunoliposomes
91-93

have become a very fashionable area of research over the past decade. Attempts to

improve currently used liposomal cancer treatments have shown positive results 94, 95.
While antibodies are the most common protein used for active targeting blood
transport proteins such as transferrin and albumin, come in close behind. Transferrin, a
protein that transports iron in the blood, is the most common non-immune targeting agent
used in cancer treatment. Transferrin is a useful targeting moiety because it preferentially
binds to malignant tumor cells because of increased presentation of transferrin receptors
on the cell surface. The high specificity of transferrin and the high levels of endocytosis
make this mechanism a popular method for targeted drug delivery. Both nanoparticles
and liposomes have used this targeting mechanism and have shown good results.
Transferrin directed targeting to malignant tumors has been performed by many
groups. Liposomal doxorubicin is again the drug of choice for many studies targeting
malignant tumors via the transferrin endocytotic pathway. One recent study showed more
than a five-fold increase in tumor doxorubicin concentration over the free drug and a 44%
increase over the PEGylated liposomal doxorubicin delivery system 96. This study did
show an increase in liver uptake of the transferring targeted drug, but other RES organs
saw a decreased concentration. This study also shows a similar circulation time to the
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untargeted drug. Another study 97 loaded paclitaxel inside nanoparticles and targeted
them using transferrin on the nanoparticle surface. Mice that were treated by untargeted
paclitaxel nanoparticles showed increasing tumor volume after ~50 days but at 80 days
the tumor volume had decreased slightly in the targeted group. This study showed
increased lifetime of mice compared with controls with the only death coming after 3
months of treatment and was seemingly unrelated to cancer. Several reviews that cover
transferrin as a targeting agent for drug delivery are available 97-100. Transferrin has also
been utilized to mediate endocytosis for nanomaterials specializing in gene delivery 101.
Lactoferrin is a related enzyme in the transferrin family that was recently used as a
targeting protein to achieve gene delivery of nanoparticles to the central nervous system
(CNS) 102.Comparison of lactoferrin-based targeting to transferrin-based targeting
showed a 5.2 times increase in CNS delivery over unmodified nanoparticles and a 2.3
times increase over transferrin modified nanoparticles 103. Several quality reviews have
been published in the area of gene delivery and can be consulted for further information
on this elegant medicinal treatment regimen 104-106.
Actively targeted drug delivery systems such as those described here are usually
delivered systemically, as will be discussed later in this review. The nature of targeted
drug delivery must give a certain level of freedom to the particles so that they can
preferentially accumulate in the tissues to which they are targeted, either actively or
passively. Local delivery limits this freedom, although there are distinct advantages of
local delivery which will also be discussed in the next section.

32

2.5.

Methods of Drug Delivery or Administration
There are two major methods of drug delivery; systemic and local delivery 17, 107-
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. Systemic and local delivery both have distinct advantages and disadvantages which

are important to discuss 10, 108. A good understanding of the limitations and advantages of
each delivery method will enable the researcher or clinician to make well-informed
decisions about how to approach a particular treatment 112-114. The majority of the work
published in drug delivery over the past several decades has focused on systemic drug
delivery through intravenous administration 13, 14, 85, 99, 99, 115, 116. However, this does not
necessarily an indicator that it is a model which affords better efficacy, though it may
have garnered some favor in part because it is viewed by many as a more sophisticated
mode of delivery.
2.5.1.

Systemic Delivery
Systemic delivery carries a drug which is delivered via the circulation to its target
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. This method of treatment carries the drug everywhere in the body and gives the

therapeutic drug access to nearly any location so that it can play its therapeutic role. This
method is useful for giving the drug this unrestrained access if the drug is capable of
distinguishing its therapeutic role from other deleterious functions it can play in the body.
However, this is rarely the case. As we have discussed previously, many
pharmacotherapeutics cause side effects, these side effects often bring about the use of a
controlled delivery vehicle in an attempt to diminish these effects 118, 119. Also, many
drugs are only needed in one specific area of the body to perform their therapeutic
function. For example, cancer is often restricted to a tumor, and a chemotherapeutic agent
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need only be in high concentrations in the location of the tumor (though metastasis
prevention through systemic delivery could be useful, but this comes at a high cost to the
patient 119, 120.) Spinal cord injury is another example of a disease for which the drug is
only needed locally. The deleterious events following spinal cord injury are mostly
isolated to the injury site, and thus only require local treatment.
There are many different routes of administration to deliver a drug to the entire
system. Intravenous delivery is the most direct for most applications because systemic
delivery is achieved by being transported through the circulatory system 121. However,
this is not the only administration route and many others have been examined and show
efficacy. Examples of other administration routes are: oral delivery 122, delivery to the
lungs and nasal cavity, often through aerosols123-127, buccal mucosa 128, topical or
transdernal administration 129-131, ocular delivery 132, 133, as well as several others 134, 135.
Some examples of systemic delivery were discussed in the previous section on active
targeting.
2.5.2.

Localized Delivery
There has been a large effort made over the past three decades to develop

effective treatments for the diseases which plague mankind. Much of this work has
focused on drug delivery and on taking advantage of potential which this field carries 23,
28, 75

. Here, we will focus on local delivery of drugs for the treatment of disease. Much of

the work done using drug delivery vehicles for the controlled release of drugs requires
targeted delivery, either by passive delivery or through active targeting, in order for them
to be effective. However, as will be discussed in more detail in a later section of this
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review, there are significant limitations to the successful treatment using a targeted
nanoparticle. The immune system is adept at removing foreign substances, and
nanoparticles are no exception 85. However, this loss of drug would be drastically reduced
if the nanoparticle based therapy could be directly injected at the site where it performs
its therapeutic action. This is one of several advantages to local delivery, but these
advantages must be weighted appropriately as local delivery is not appropriate for all
applications.
Local delivery, in contrast to systemic delivery, offers several other advantages
136

. First, it prevents the large scale loss of nanoparticles in the liver and other RES

organs, and limits the immune response to only the local tissue response 137. In addition,
much lower concentrations can be used because the therapeutic will not be dispersed
throughout the body, this results in less waste and thus a more cost efficient system, and,
perhaps more importantly, it limits the side effects associated with high doses and drug
accumulation in healthy tissues. Even in the most successful cases of drug delivery which
achieve around 5% of the administered drug at the targeted site, the other 95% of the
drug is distributed throughout the body potentially causing side effects 113. Local delivery
also offers the advantage of a one-time administration of the treatment, after which
sustained delivery extends therapeutic action. This is important not only for the comfort
of the patient, but also eliminates the risk of patient compliance when regular dosing is
required. In the case of local delivery, though there will be some drug which escapes, the
majority will stay localized, especially when delivered in a controlled manner from a
slowly degrading particle. This controlled release is shown to be more effective than
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weekly treatments because a low consistent dose is present. Third, the drugs can be
stabilized by the delivery system which can protect the therapeutic activity of the drugs.
There is also the advantage of local delivery of hydrophobic drugs, which have limited
therapeutic ability when administered as a free drug because of rapid clearance rates and
low bioavailability. Controlled release at the site of therapeutic need allows for effective
treatment. Fifth, controlled release of drugs over time which creates the environment for
effective treatment of the diseased site and allows for diffusion to expose and affect all
diseased cells.
One major limitation to local delivery is knowledge of the exact location where
the drug is needed and access to that location, which creates a field of interest for
scientists working on image guided drug delivery 138. For example, cancer is a common
target for nanoparticle based therapies, but cancer is hard to locate with precision and it is
often spread over large areas and can metastasize to other tissues. This exposes one
limitation of local delivery, as a therapeutic restricted to only one region cannot prevent
the systemic spread of disease. Another limitation to site specific delivery is that it is
limited to only one region, while many diseases could require the need to treat several
regions. However, there are many diseases or injuries that would make good candidates
for treatment by local delivery. One such disease which has been hypothesized to be
treatable by nanoparticles through local delivery is acute spinal cord injury. Acute spinal
cord injury occurs when the spinal cord and the surrounding tissue become mechanically
compromised and biochemical pathways which ensue cause further degradation. This
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injury is a good candidate for local delivery because the deleterious activity is confined to
the region where the mechanical insult occurred.
2.6.

Technology for Controlled Release
Controlled release is a useful component of drug delivery devices, whether for

local or systemic delivery. We have already discussed the advantages and disadvantages
of systemic and local delivery including which carrier is best, and whether local or
systemic delivery was more appropriate in a particular application. Now we will look at
some of the available systems for controlled release with a focus on drug delivery
systems and materials which have obtained regulatory approval.
2.6.1 FDA Approved Nanoparticle Carriers
As mentioned before, there are only two nanoparticle systems which are
approved by the FDA. The first to be approved was Doxil, a liposomal nanoparticle for
cancer treatment first approved in 1995 139. Doxil has been extensively discussed and
reviewed elsewhere 140-144, so we will not go into detail here. However, there has been
work attempting increase the efficacy of Doxil by targeting it to cancer. One of the most
common targeting agents is the anti-HER2 antibody which targets the p-185, or HER2,
receptor over expressed on the surface of many malignant tumor cells 145, 146. Park et al
published impressive results in a study comparing passively delivered liposomal
doxorubicin (Doxil) and HER2-targeted liposomal doxorubicin in HER2 over-expressing
tissues 146. ElBayoumi and Torchilin had success in active targeting of the FDA approved
liposomal formulation Doxil using monoclonal autoantibodies 23. Early studies by
Torchilin’s group show that monoclonal autoantibody 2C5 specifically recognizes many
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tumor tissue types but not normal, healthy tissues 147. The biodistribution of the targeted
construct was followed by radiolabeling and a small increase in RES uptake was seen
over plain Doxil with 55% of injected drug in RES organs as compared with 49% in the
untargeted treatment. The result of the targeted treatment was a decrease in tumor size to
25-40% of the Doxil treated group. Another study by Torchilin and Gupta showed a
similar 2C5 targeted Doxil therapy effectively treating brain tumors in mice 94. They
again showed a significant decrease in tumor to ~50% the size of the Doxil regime 24
days after the treatment began.
One FDA approved example of a nanotechnology based drug delivery system
which is delivered systemically is Abraxane, an albumin based nanoparticle which is
administered intravenously . Albumin is a serum protein that is commonly linked to small
molecules for delivery to tumors where it preferentially accumulates, but until recently, it
has not been used in association with nanotechnology 148. Novel nanoparticle constructs
built from albumin for the delivery of paclitaxel that did not cause hypersensitivity
reactions was designed by American Bioscience and titled Abraxane 21. Paclitaxel is
encapsulated inside the albumin nanoparticle shell and delivered to the tumor site by
passive delivery utilizing the EPR effect. Once at the tumor site, Abraxane binds to
albumin binding proteins dubbed SPARC (Secreted protein, acidic and rich in cysteine),
which are over expressed in certain cancers 19. Binding to these proteins initiates
endocytosis and increased therapeutic efficacy over the previously used delivery via
Cremaphor (non-aqueous polyethylated castor oil) 20. Delivery in the non aqueous solvent
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is thought to have inhibited the ability of albumin to bind cell surface proteins and
thereby prevent endocytosis and reduce the drugs impact 149.
2.6.2.

Polymeric Drug Delivery Systems for Local Controlled Release
One of the first, and likely the most successful drug delivery systems is Gliadel
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. This is a depot for delivery of a chemotherapeutic drug to brain cancer which is

constructed from (poly [carboxyphenoxy-propane/sebacic acid] anhydride wafers loaded
with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). This technology was developed
around 1980 by Robert Langer, received FDA approval in 1996, and expanded approval
in 2003 for local treatment of brain cancer using up to eight of the drug loaded wafers at
the site of cancer 150-152. There was significant improvement in outcomes shown for those
treated with Gliadel in several clinical trials 153-155. There were 59 patients available for
long-term follow-up and 11 were alive at 59 weeks. Of these 11, 9 received the Gliadel
wafers and two received unloaded wafers 155. There was an increase in survival of treated
patients to a median of 13.8 months compared with 11.6 months in the untreated group
155

. Despite the success shown in these studies, there is still some concern about efficacy

156 157

.

Lupron Depot is a PLGA based drug delivery system which releases an analogue
of gonadotropin-releasing hormone to stimulate hormone production by the anterior
pituitary gland 158. It is used to treat a several conditions including endometriosis,
prostate cancer, and precocious puberty 159-161. As can be seen from Table 2, the PLGA
formulation is made up of microparticles for the intramuscular administration of the drug
for controlled release over the following several months 162, 163. Lupron Depot originally
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received FDA approval in 1989, after the delivered drug was approved in 1985 showing
efficacy in treating prostate cancer 158, 164, 165. It was successful in treating patients by
chemical castration instead of surgical castration and the results of the study showed that
the chemical castration simulated the surgical castration well 158. It received approval
after seeing success in other applications later 166, 167.
Another PLGA based system for the controlled release of drugs through the
polymeric implant. The delivery vehicle, called OncoGel, is constructed of a poly
(lactide-co-glycolide) and poly (ethylene glycol) (PLGA-PEG-PLGA) tri-block
copolymer for local administration and the controlled release of the incorporated
paclitaxel chemotherapeutic agent 168. OncoGel showed a controlled release profile over
50 days and saw less than 0.1% of the drug able to spread to other organs and blood.
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Table 2: A list containing some of the depots for controlled release of drugs
based on poly (lactide), poly (glycolide), and their copolymers 169.

Also, animal studies showed efficacy with a dosage 10 times lower than previous studies
without the polymeric delivery vehicle. OncoGel has not received FDA approval yet, but
it is currently undergoing clinical trials to evaluate its ability to treat cancer in tandem
with radiation therapy 170, 171. The efficacy of OncoGel clinically and future perspectives
are well reviewed elsewhere 172.
The controlled release systems reviewed here are by no means a comprehensive
list of the technologies which have seen success. However, it does give insight into some
of the technologies and materials which have shown efficacy. Table 2 shows a snapshot
of some of the successful drug delivery vehicles based on the PLGA family of polymers.
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This illustrates the value of micro-scale particles and begs the question of whether
nanoparticles can play a valuable therapeutic role. While the number of nanoparticles that
have been approved is limited, increasing research in this area and a medical community
that is growing in its knowledge, understanding, and acceptance of nanotechnology paves
the way for effective nanomedicines to reach the marketplace.
2.7.

Nanotechnology for the Treatment of Spinal Cord Injury
Nanomaterials have a great potential to effectively treat spinal cord injury and

there has been work which has seen some success, though there is still no approved
therapy 173. Several studies have been performed to evaluate the therapeutic efficacy of
nano-materials for controlled release of different therapeutic agents in injured spinal cord
models. Several different materials have been evaluated including silica174, PLGA175, 176,
liposomes177, and poly(HEMA) along with other hydrogels 175, 176, 178.
As discussed previously, there are two different delivery methodologies which are
possibilities for nanoparticle mediated treatment; systemic and local delivery. Systemic
delivery exposes the drug to many different tissues throughout the body and can treat
systemic disease. Local delivery allows for sustained release of therapeutic doses of the
transported drug at a specific injury site. This is only an effective treatment if the disease
is confined to a certain region. However, side effects which often accompany
pharmacotherpeutics can be limited by local delivery. There are other advantages and
disadvantages for both depending on the specific application which have been addressed
herein. There are certainly nanotechnology-based systems that are not mentioned which
have been and will be evaluated in the spinal cord. Here we aim to give an overview of
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some of the more recent work in the field, but it is not an extensive review, as there are
other reviews on the subject 178-180.
The treatment of central nervous system diseases, including SCI, using
nanoparticles has been explored by several groups 181182. One major formulation for
systemic delivery is poly (butyl cyanoacrylate) (PBCA) nanoparticles which have
consistently exhibited an ability to deliver to the CNS and a capability of penetrating the
BBB with little evidence of toxicity 183, 184. Several groups have shown the versatility of
this delivery mechanism for delivery of a variety of therapeutic drugs in animal models
185 186

. In vitro, protein delivery by PBCA nanoparticles 187 to the CNS has also been

explored. Other nano-materials for treatment of neurodegenerative disorders are reviewed
elsewhere 188.
Local delivery can address some of the limitations of systemically delivered drug,
if the application is appropriate. Local administration, where the drug is applied directly
to the diseased region, is often a good alternative to systemic delivery. Biodegradable
nanoparticles which are loaded with a therapeutic drug are used to allow for a
controllable, region specific treatment regime. Recently, several studies using PLGA
nanoparticles loaded with MP administered topically at the lesion site were performed110,
189

. Other studies have also investigated the local delivery of MP using dendrimer-based

nanoparticles 190.Improvements in functional recovery and neuroprotection were
observed in both studies. However, with questions remaining about the therapeutic
efficacy of MP, there will be concerns about the described system. Systemically
administered PEGylated liposomes showed an ability to cross the blood-spinal cord
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barrier to treat the disease 177. Poly (L-Lactic acid) (PLLA) nanoparticles loaded with
prostaglandin E1 (PGE1) were also evaluated for their ability to improve locomotor
function in rats after induced spinal cord lesions 191. This intravenously administered
nanoparticulate delivery system showed a significant improvement over saline control
and a similar effect to the liposome delivered drug 191. PLGA nanoparticles have also
been utilized to deliver therapeutic proteins to the spinal cord 192. This study showed that
local injection of encapsulated glial cell line derived neurotrophic factor (GDNF) could
achieve sustained release from the particle and improve neuron survival and locomotor
function in rats 192. There are also other nanoparticles constructed from ceric oxide which
show neuroprotection in vitro 193. These 3-5 nm particles are theorized to have antioxidant activity which enables them to function as neuroprotective particles. However,
there is some concern of toxicity for ceria nanoparticles as well as other oxide
nanoparticles 194.
PLGA nanoparticles have also been used in combination with hydrogels to
facilitate controlled release of a variety of therapeutics 175, 176. Controlled release of one of
these promising pharmacotherapeutics, anti-NogoA, offers sustained release which
eliminates the need for an external pump or catheter, thus reducing the risk of infection
175, 176

. These studies have used nanoparticles for the controlled release of drugs in

combination with hydrogels in an effort to maximize therapeutic efficacy 195. They use a
hydrogel constructed of methylcellulose and hyaluronan polymers with embedded PLGA
nanoparticles loaded with a drug 176. This combination of PLGA particles and the
hydrogel actually stabilized the hydrogel matrix. These composites showed no
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deleterious effects in the two weeks following injury after insertion into the intrathecal
space. One study utilizing this system showed a reduction in side effects typically
associated with Fibroblast Growth Factor-2 (FGF-2), the drug delivered in the PLGA
particles. This efficacy illustrates the potential for a combination system such as the one
described.
Another area of research for protection of the spinal cord after injury centers on
carboxyfullerenes. These compounds have shown to have anti-oxidative as well as antiapoptotic capabilities 196, 197. This anti-apoptotic ability functions through the inhibition of
glutamate receptor excitotoxicity. These neuroprotective abilities have drawn attention to
the carboxyfullerenes and on their potential to treat not only spinal cord injury, but other
neurodegenerative disorders as well 196, 198. However, despite the efficacy shown in these
compounds, there is still much that is not known and this enigma elicits trepidation in the
regulatory community.
2.8.

Estrogens Encapsulated into Nanoparticles
There are several groups who have encapsulated estrogens into nanoparticles,

most commonly estradiol. However, due to the fact that it is a well known drug, its
hydrophobic nature, and that it has a reputation for side effects, it has been used primarily
as a model drug 69, 199-201. Despite its use as a model drug, there has been some work
using 17β-estradiol as a therapeutic drug delivered by nanoparticles. One such study
examines the ability of the hormone drug to treat Alzheimer’s disease using a
nanoparticle carrier designed to cross the blood-brain barrier 202. PLGA nanoparticles
were used to encapsulate the drug and Tween-80 was used as a coating to facilitate the
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brain delivery of the estrogenic drug. The study observed an increase in brain
accumulation of the drug when Tween-80 was used as a coating, indicating that this
coating increased uptake into the brain. In addition, there was a noted reduction in
expression of amyloid beta-42, which has been implicated in the pathology of
Alzheimer’s disease. In addition to systemic delivery, there has also been work on the
topical application of estrogenic nanoparticles for the treatment of menopausal symptoms
67

. These treatments have used PLGA and have showed increased uptake and a controlled

release to limit side effects associated with the drug.

2.9.

Limitations to Nanoparticle Based Targeting and Drug Delivery
There are several major hurdles that must be overcome for much of this

technology to be effective and reach the market 9. Much of the work in nanotechnology
has focused on systemic administration and accumulation at diseased sites, but there are
common misconceptions in the field which can lead to an unrealistic expectation of the
treatment efficacy of many nanoparticulate treatment modalities. Here, we will discuss
some of these misconceptions with an eye on the future of nanotechnological
development, which we believe has a bright future of effective treatments for a variety of
diseases. However, we must be honest about the major barriers in the field in order to
make meaningful steps towards future innovation.
2.9.1. Poor Targeting
As can be inferred from the recent work in the field of targeted drug delivery, the
main barrier to effective treatment through systemic delivery is poor targeting. Systemic
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administration of nanoparticulate drugs, most often through intravenous injection, has
made great claims of success and of ther future potential of such treatments, but there
appears to be little improvement in the efficacy of these treatment options 31. While
increased circulation time and targeting moieties have improved accumulation at the
target site, therapeutic efficacy for many applications necessitates even better targeting.
While there is an increase in accumulation of nanoparticles in many sites as
described by the EPR effect, it is not as large of an increase as it often appears when
reading the literature. It has been reported that the amount of drug delivered via
nanoparticles which actually reaches the target site is typically less than 5% 113. This
indicates that 95% is elsewhere in the body. This is unchanged by targeting moieties on
the outside of the particles. Particles in a certain narrow range (already discussed
previously in this review) are able to avoid clearance to some degree and accumulate in
tissues where leaky vasculature exists. Despite this increase in accumulation, which, no
doubt, does occur, the amount of drug reaching the targeted site is far from ideal.
Active targeting is thought by many, largely because of a body of misleading literature, to
be a technology which can effectively corral the nanoparticles to the site where they play
their therapeutic role. However, ‘decorated’ nanoparticles are subjected to the direction
of the blood flow and follow the circulation in the same way as undecorated particles 10.
The targeting moiety, or ligand, can only interact with its receptor if the distance between
them is less than a half a nanometer 113. This distance is extremely limiting. However,
once the particles decorated with targeting moieties reach these tissues which possess the
receptor, the targeting agent can anchor them and even increase cellular uptake of these
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particles, potentially increasing efficacy. An example of this, which has been referenced
in a review on some of the limitations discussed 10, is shown in Figure 12. This Figure
shows no major difference in accumulation of antibody targeted liposomes compared
with untargeted in the tumor. There is an increased uptake of the anti-HER2 antibody

Figure 12: The percentage of the radio-labeled immunoliposomes
accumulated in the tumor is not significantly different from liposomes which
are not targeted with the anti-HER2 protein. However, the inset shows
internalization of the liposomes into the cancer cells. Here, the antibody
modification makes a large difference. Image taken from Kirpotin et al. 111
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surface decorated liposome though, as can be seen in the inset in the Figure 203. This is a
typical response as if there is a reported increase in accumulation due to targeting it is
typically small and not significantly different from the untargeted particle 10.
A discussion of these limitations does not invalidate a discussion on advances
which are being made, both in so-called passive targeting and in active targeting. There
have been two FDA approved nanoparticle delivery systems (discussed earlier is this
review). These both utilize passive delivery based on the EPR effect, but there has been
work on increasing efficacy through active targeting. We are not attempting to discredit
or cast doubt on either the work done in the recent past or on the potential that these
particles have to effectively treat a variety of diseases. Many of these diseases pose
complex pathologies which make them difficult to treat with any other therapies, and
nanotechnology appears uniquely positioned to provide treatment. However, it is vital to
have an understanding of the limitations present in the field so that meaningful advances
can be made.
One answer to the limitations seen in the ability to target drugs to the site where
they are needed is the use of local delivery. There are several therapies have been
approved utilizing controlled release of drugs at a specific site 153, 155, 166, 167, 169. If the
injury or disease site is known and is accessible, direct administration of a drug delivery
system that can deliver a therapeutic dose over time is beneficial, especially in contrast to
the potential of a systemically delivered drug. There are only certain situations where
such an application is appropriate, but if applicable, many of the limitations discussed for
systemic delivery are not present when local delivery is achieved.

49

2.9.2. Surface Modification and Immune Response
Another necessity for systemically delivered drugs is increased circulation time
which is an imperative for efficient delivery. The clearance of foreign materials from
both the circulation and the tissue is efficient and is a major barrier to effective treatment,
especially when targeting is necessary 9. Questions as to protein and enzyme stability and
efficacy in vivo once applied to a nanoparticle system also remain. Other limitations
include the ability to add the modified PEG groups after drug formation, which is an area
that has seen much improvement over the last few years9. The maintenance of attached
targeting ligands once drugs are in the circulation is also an issue limiting the application
of these treatment options 9. If the targeting ligands are lost before localization at the
tissue then there is reduced internalization and thereby, reduced efficacy.
Another area that limits the application these treatments from reaching the market
is the ensuing immune response. This is related to the surface modification limitation
because the immune response and clearance rate of the particles are directly related to
their surface, as that is the chemistry with which the body interacts. Methods to reduce
the immunogenicity, such as PEGylation and the use of liposomes as carriers, have made
strides toward this goal, but it remains a significant barrier 16.
2.9.3. Sterile Formulations and Manufacturing Limitations
Another major barrier is the preparation of sterile formulations for treatment 204.
Many of the sterilization methods compromise the integrity of the therapeutic or polymer
scaffold 205. There are methods that can be used, such as irradiation, which remains one
of the most popular methods of sterilization for polymeric delivery vehicles, but
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questions remain as to the efficacy of the sterilization treatment and its potential effect on
many proteins and polymer delivery systems 204-206. The ability to scale up the
manufacture of nanoparticles for marketing once a formulation is approved is also a
limitation 114.
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CHAPTER THREE
SIGNIFICANCE AND SPECIFIC AIMS
3.1.

Clinical Significance

Secondary injury plays a key role in the pathology of spinal cord injury.
Inflammation, free radical damage, ionic imbalance, and apoptosis are all culprits in the
etiology of secondary SCI. The damage caused by these secondary injuries begin as soon
as the injury is sustained, but continues for an extended period of time as healing takes
place. However, it is during the first few days following the injury when the most critical
damage occurs. Thus, if an effective treatment option is administered early after injury
treatment continues for one to two weeks following the injury, much of the damage could
potentially be prevented.
Sadly, the current standard for treatment of SCI, methylprednisolone, is highly
controversial and its efficacy has been questioned by many experts in the field. This
leaves physicians with no good option for treating SCI. In answer to this need there has
been a body of research to try and find an effective treatment option 33, 41, 56. One such
treatment which has garnered attention is 17β-estradiol, an estrogen, which has been
shown to be effective at ameliorating many of the effects of secondary SCI. This
therapeutic effect can be attributed to the multiple therapeutic roles which the estrogen
can assume. This estrogen is an effective anti-inflammatory agent, a potent anti-oxidant,
and is also capable of restoring ionic homeostasis and preventing apoptosis. All of these
effects combined have drawn attention to 17β-estradiol as a potential neuroprotective
drug for treatment of SCI. However, there are some limitations to the use of this estrogen.
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These include possible side effects due to the estrogenic nature of the drug, and high
doses, which exacerbate side effects, necessitated by rapid local clearance and systemic
biodistribution of the drug.
Here, we propose as a solution a biocompatible, biodegradable, PEGylated polymeric
nanoparticle for controlled release of the drug and resistance to uptake. This nanoparticle
will enable slow release of the drug in therapeutic levels at the site of injury. Local
administration and the controlled release from the nanoparticle will keep the drug
localized and prevent much of the drug clearance associated with intravenous delivery.
The controlled release should be able to sustain a therapeutic concentration of the drug
while limiting the dose exposed to the body in an effort to limit side effects.
In the long term, this work will pave the way for the development of an effective
therapy which will prevent much of the damage caused by SCI and restore the patients to
a high quality of life. The platform proposed here can also be applied to other
therapeutics to be locally administered and could provide a platform for other novel
therapies to be effectively delivered with minimal side effects and low therapeutic doses.
The proposed nanoparticulate estrogen delivery system may also be effective at
treating other diseases. Estrogens are considered to be potentially influential in the
pathological development of several major diseases. The neuroprotective role which
estrogen plays in the treatment of SCI could be translated to treatment of Parkinson’s
disease, Alzheimer’s disease, and multiple sclerosis should estrogen (or a lack of
estrogen) prove to be implicated in the pathology of these diseases. For example, many
consider estrogen to be involved in the pathogenesis of Parkinson’s disease, as there are
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many conditions which result in a slowed estrogen production which have been
implicated as risk factors for the disease 11. In short, an effective therapy to facilitate the
controlled release of estrogens, while limiting the side effects commonly associated with
estrogen treatment, could not only transform the currently known therapeutic realm for
estrogens, but could expand it to treat diseases in which estrogen’s role has not yet been
elucidated.
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3.2.

Specific Aims

Specific Aim I. Development and characterization of nanoparticles for sustained
release of 17β-Estradiol as a treatment for spinal cord injury
Hypothesis: In this aim, we will establish an effective formula and ideal
conditions for effective encapsulation of our estrogenic drug in nanoparticles as well as
characterize the particles. The characterization of the particles which are designed for
therapeutic treatment is critical. We will characterize these particles by determining
encapsulation efficiency, particle size, and in vitro release profile.
We will first determine a formulation for the drug containing particles by using
varying poly (ethylene glycol) (PEG) content to find the maximum encapsulation
efficiency. We will then lyophilize the formed nanoparticles for long term storage. Size
of the nanoparticles is evaluated here by both dynamic light scattering (DLS) and atomic
force microscopy (AFM). The goal of using both methods for analysis is to ensure
accuracy and to observe if there is any level of aggregation. Size of the nanoparticles is
important for diffusion in the tissue, controlled release rate, and can affect the body’s
ability to clear the particles. Degree of aggregation is also important as the particles
should be stable individually.
Dosing will be evaluated based on the in vitro release rate with an eye towards
translation of the system into in vitro and eventually in vivo studies to evaluate efficacy.
The determination of the in vitro release rate is tricky for hydrophobic drugs such as 17βestradiol, so we propose the use of a protein, albumin, which is involved in the transport
of hydrophobic small molecules in the body, to aid in drug transport. Albumin carries
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estrogens and other steroid molecules in the body, and can function to separate the drug
using a dialysis based delivery system described herein. This method will be evaluated
using PLGA nanoparticles loaded with estrogen and with a liposome with incorporated
dexamethosone. The use of two drug delivery systems as well as two drugs will illustrate
the utility of the method.
Specific Aim II. In vitro analysis of the estrogen loaded nanoparticles in a
neuroblastoma cell model.
Hypothesis: We will evaluate the neuroprotective effect of the sustained release
estrogen in a neuroblastoma cell culture model challenged by both glutamate, an
apoptosis inducing molecule, and hydrogen peroxide, which simulates oxidative stress.
The newly developed nanoparticle delivery system must be evaluated for efficacy in a
relevant cell culture model to determine its ability to treat the events following SCI. The
cell model used here will be a neuroblastoma cell model which should respond to similar
stimuli as native nervous system cells from the spinal column.
This evaluation will be done by first illustrating the retained activity of estrogen
loaded into nanoparticles by dissolving the polymer shell and delivering the once
encapsulated estradiol alongside free estradiol to demonstrate a similar protective effect
between the two. This, as well as an evaluation of the neuroprotective effect of the
estrogen delivered via the nanoparticle, is demonstrated with a glutamate challenge to
mimic glutamate excitotoxicity of the cells in the region of the injury.
Second, a hydrogen peroxide challenge, to mimic the oxidative stress
following injury, will be used to evaluate the therapeutic ability of the developed
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treatment. A dose dependent study to determine the best dose for therapeutic efficacy will
be carried out. This study will evaluate the neuroprotective effect of the hormone when
delivered by the nanoparticle system through controlled release. There will also be a pretreatment time study performed. This is necessary because of the controlled release
component of the delivery system. Because the drug is released slowly over time, the
maximum therapeutic effect should not be expected immediately upon administration,
but rather should be expected after a time for release. This pre-treatment study will
evaluate the efficacy as more time is allowed for drug release before the challenging
agent, hydrogen peroxide again for this study, is added to simulate the oxidative stress
after injury.
These studies should shed some light on the dose, pre-treatment time, and
therapeutic effect to be expected as this treatment regime is translated to an in vivo
animal model for evaluation. However, there are some limitations to the in vitro cell
culture model used here. The neuroblastoma model is a cancer cell model and thus does
not exhibit the sensitivity that natural cells would show towards estrogen as well as some
of the challenge agents. Accordingly, it is appropriate to further study these responses in
a primary cell culture model to allow for a smooth transition into an animal model using
appropriate, experimentally supported doses and treatment expectations.
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Specific Aim III. In vitro evaluation of the proposed delivery vehicle using primary
chicken dorsal root gangion neuron cell culture model.
Hypothesis: The dorsal root ganglion neuron cell culture model is a clinically
relevant model that should permit effective dosing to be determined. This primary cell
line will provide a useful comparison to the neuroblastoma model utilized in prior
experiments and should set the stage for translation into an in vivo small animal model
for evaluation of the treatment. Here, we will perform the same dose dependence and pretreatment time experiments that were performed on the neuroblastoma cell model. This
will enable a useful comparison in response and provide the researchers with valuable
data to take the treatment to the next stage of testing.
Hydrogen peroxide will again be used as the challenging agent and will illustrate
the neuroprotective effect of the drug. All appropriate controls will be performed to
establish nanoparticle efficacy. As mentioned, the overarching goal of these in vitro
studies is the translation of the treatment which is being evaluated into an animal model
as the next step towards providing a useful treatment for those plagued with SCI.
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CHAPTER FOUR
DEVELOPMENT AND CHARACTERIZATION OF NANOPARTICLES FOR
SUSTAINED RELEASE OF 17β-ESTRADIOL AS A TREATMENT FOR SPINAL
CORD INJURY
4.1.

Abstract
Here, we report a both the development and characterization of a polymeric

nanoparticle for therapeutic application to acute spinal cord injury and a technique to
evaluate the drug release profile of hydrophobic drugs from drug delivery modalities.
First, we show the loading potential and size of the developed PEGylated nanoparticle.
We show that a high loading efficiency can be achieved and that the size and materials
are appropriate for a biocompatible, controlled release system for treatment of
traumatized spinal tissue. Second, we develop a new method for analyzing the drug
release profile of hydrophobic drugs, and use the newly formulated particle along with
liposomal dexamethosone to evaluate the release capability of this system. The drug
release profile provides insight into translation of drug delivery systems into living
models. Release profile analysis is complicated because many of the materials used to
deliver the drugs, including most polymers, dissolve or break down using the current
evaluation techniques. To address this issue, we use proteins as drug carriers in vitro.
This protein mediated transport is how many hydrophobic molecules, including steroid
hormones (estrogens, serotonin, testosterone, etc.), are transported in the body. Thus, it is
reasonable to use these proteins in vitro to approximate the in vivo release of drugs.
Here, we have shown that the use of a dialysis based system utilizing such a protein, the
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ubiquitous serum protein known as albumin, as a drug carrier to aid in evaluating in vitro
release rate. Our results indicate that the method is capable of elucidating the release
profile in a diverse set of drug delivery modalities. We evaluated the method using
liposomes and PLGA nanoparticles and two model therapeutic hydrophobic drugs: 17βestradiol and dexamethasone.
4.2.

Introduction
Recently, there has been a growing interest in controlled release and its

implications for future medicine. A variety of drug release modalities have been used for
disease treatment ranging from polymeric wafers 153 to polymeric nanoparticles 82, 206 and
liposomes built from lipids mimicking the cell membrane 22, 203, 207. Nanoscale particles
constructed from biodegradable polymers or lipids with incorporated drugs have
increased because of their useful properties including biocompatibility, tunable
degradation rates, varied useful morphologies, long circulation potential, and sustained,
low dose release of therapeutic drugs 72, 206, 208, 209. The performance evaluation of these
drug delivery vehicles necessitates a method of determining the in vitro release profile of
as they elute from their carrier. Characterization of these drug delivery modalities is
imperative for translation from the bench-top to the bedside.
The size of nanoparticles is vital to the drug release rate as well as the ability for
particles to be delivered to a specific site by the enhanced permeability and retention
effect (EPR). It also affects the diffusion rate in tissues. The biodistribution of
nanoparticles and liposomes delivered systemically by intravenous injection is a factor of
their size 77. Thus, it is important for particles to have a relevant size and for it to be well
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characterized before implementation in vivo. Evaluation of the degree of aggregation in a
nanoparticle population is also an important characterization step.
PLGA-PEG nanoparticles are naturally resistant to uptake in the body because of
the hydrophilic PEG coating. This coating will limit rapid opsonization and clearance by
preventing adsorption of proteins and molecules. Because this formulation is designed to
be administered locally, there is likely not as much attrition in nanoparticle numbers due
to filtration by the reticuloendotheliel system (RES) and opsonization and uptake by
scavenger cells as there would be for intravenously administered nanoparticles.
The FDA issued regulatory guidance to encourage experimental methods which
reliably translate from in-vitro studies to in-vivo 210. They also state that ““Bioavailability
studies where humans are used as test subjects should be minimized by implementation
of in vivo dissolution standards that reflect in vivo drug performance.” 211 This translation
from in-vitro to in-vivo requires an understanding of how the delivery systems will work
in vivo, which necessitates an in vitro evaluation method which provides good in-vitroin-vivo correlation (IVIVC). This is a key component of drug delivery evaluation for
safety, efficacy, and translation into clinically relevant models.
In vitro release of hydrophilic drugs is relatively easy to perform in aqueous
buffer. However, hydrophobic drug release is complicated by low solubility in aqueous
solvents. Sink conditions, which dictate that the amount of solvent must be triple the
solubility limit of the drug to perform dissolution characterization, must be met to
appropriately evaluate the dissolution, or release, of a drug over time. These sink
conditions can be very difficult to meet in the case of poorly soluble drugs. This difficulty
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has led to attempts to increase the solubility, of these drugs to make sink conditions more
achievable. This is commonly done by adding surfactants, inorganic salts, and organic
co-solvents (such as ethanol) to increase solubility 211. Surfactants are not ideal for
controlled release modalities because many dissolve the carrier matrix resulting in
premature release. Salts can aid in solubility, but do not provide a large improvement.
Ethanol does not dissolve most biodegradable polymers including poly(mono-ethers),
like PLGA, but evidence suggests that the integrity of the polymer is compromised likely
due to large pores which appear after ethanol treatment. These strategies can affect the
solubility of the drugs, but all have major limitations and none play an active role in the
transport of the drug and a system (dissolution methods and their limitations have been
thoroughly reviewed elsewhere and will thus not be discussed in detail). In addition, the
use of additives not naturally present in the body may alter the release yielding a less
accurate profile.
To address the issue of in vitro evaluation of the release of many poorly soluble
drugs, we propose the use of albumin as an active transport vehicle in a dialysis system
for analysis of drug release profile in vitro. Albumin has been used in tandem with many
other additives to increase solubility of some drugs 212, 213, but to our knowledge there has
been no work illustrating the distinct advantage of albumin as a natural protein which can
function both in vitro and in vivo as a drug carrier. Utilization of the proteins that are
involved with physiological transport in vivo gives early insight in-vitro to what the
release profile will be when translated to an animal model.

62

Albumin’s physiological function is in the transport of poorly soluble molecules
in the circulatory system. There are many proteins whose primary function is transport,
but albumin is the most abundant in the serum (3.4-5.4 g/dL) and can carry a diverse set
of molecules and can cross various barriers in the body to deliver them where they are
needed 214. This protein can then be used to perform its natural function utilizing a
dialysis membrane with a large pore size allows for the easy passage of albumin across
the membrane while preventing drug carrier loss. This system allows for passive
diffusion of albumin both without bound drug and albumin-drug complexes for the active
removal of released drug from the drug carrier. There are two advantages of this in-vitro
delivery system. First, the protein involved in transport of many poorly soluble drugs is

Figure 13: Crystal structure of bovine serum albumin protein model from
the Protein Data Bank (PDB) database.
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used to mimic the in vivo transport of the drugs and provide an accurate in-vitro-in-vivo
correlation (IVIVC). Second, the increased solubility of these drugs makes the
achievement of sink conditions manageable for many drugs. One limitation of this
albumin dialysis system is that not all hydrophobic drugs can be actively transported by
albumin. There are many drugs, especially steroidal drugs, for which this system will
likely perform admirably, but there are limitations. However, hydrophobic molecules
which play a functional physiological role, or drugs which are structurally similar, will
likely be transported by albumin or another transport system.
4.3

Research Methods

4.3.1. Materials
L-α-Phosphatidylcholine(PC)

from

egg

yolk,

Cholesterol

(Chol),

and

Dexamathasone (DEX) were purchased from Sigma- Aldrich (St. Louis, MO). 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene

glycol)-2000]

(DSPE-PEG2000) (PEG-lipid) was purchased from Avanti (Alabaster, AL).Phosphate
buffered saline (PBS) was purchased from VWR (West Chester, PA). 17β-estradiol,
50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw 7,000-17,000), and
PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were purchased from SigmaAldrich (St. Louis, MO).Bovine serum albumin was purchased from SeraCare (Milford,
MA ). DMSO, Chloroform, Acetone and other organic solvents were purchased from
VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro (Manassas, VA).
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used
for specrophotometic analysis of an MTT-based cell proliferation assay and to analyze
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steroid concentrations. Spectrum/Por Biotech Cellulose ester membranes with a 300,000
kDa (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for
dialysis.
Nanoparticles were characterized by zeta potential measurements using a
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the
appropriate particle concentration. Data presented are the average of the measurements of
three separately prepared samples each analyzed in 5 runs.
The estrogen nanoparticles were characterized using an Asylum Bio-MFP3D
atomic force microscope (Asylum Research, Santa Barbara, CA). AFM experiments were
conducted in tapping mode in ambient conditions using Olympus AC160TS cantilevers
backside-coated with aluminum with a spring constant of ~40 N/m.
For AFM sample preparation, a mica substrate surface was washed in reagentgrade acetone and then thoroughly rinsed with de-ionized water. The top layer of mica
was then removed by adhering tape to the surface and quickly removing it, thus revealing
a new layer of atomically flat mica for imaging. A 10-20 µL drop of the nanoparticle
suspension was placed on the substrate surface, incubated for 6 min, and dried under
airflow.
4.3.2 Formulation development and loading efficiency
4.3.2.1.

PLGA nanoparticle recipe formulation study

Before the drug loaded nanoparticle could be characterized and tested in disease
models, the exact nanoparticle formulation had to be elucidated. The drug loading
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efficiency was of paramount importance since this strongly dictates the cost efficiency of
producing such a therapeutic. In order to determine the most efficient formulation for
loading, two different polymer recipes were tested. First, 12.5 mg of Poly(D,L-lactide-coglycolide) (Mw 7,000-17,000) was mixed with 5 mg PEG-PLA (poly [ethylene glycol] –
poly [lactic acid]) copolymer (Mw 5,000 PEG:5,000 PLA) in acetone. This formation is
designated by its PEG content of 25% by weight. A second formulation with 10% PEG
was also tested. This formulation used 20 mg of PLGA mixed with 5 mg PEG-PLA
copolymer. Both formulations began with 2 mg 17β-estradiol as the starting weight. The
10% PEG formulation was determined to have a better loading yield and was used in all
ensuing work done on this project.
4.3.2.2.

Synthesis of PLGA nanoparticles

PLGA nanoparticles were chosen to deliver the drug in this study because they
have a proven track record of safety in humans 82, 206. Nanoparticles will be constructed
using the nanoprecipitation method as previously described 215, 216. Briefly, 50:50 PLGA
was mixed with PEG-PLA copolymer, and an estrogen in 10:2.5:1 (wt.) ratio, as decided
in the formulation study. This was dissolved in acetone to obtain a 5 mg/mL polymer
solution. This solution will be added drop-wise to 20 mL of de-ionized water in an
ultrasonic water bath and sonicated for 30 minutes. The formed particles then will be
separated by centrifugation (7500 rcf) for 2 hours, washed three times with de-ionized
water and resuspended in PBS buffer.
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4.3.3

In vitro drug release profile
Typically, drug release is performed in a physiologically relevant solution, such

as PBS. Of course, this can only be done with drugs that are soluble in aqueous solutions.
One way to address this solubility problem is to use a solvent in which the drug is
soluble, but does not dissolve the polymeric shell. We performed such an experiment
using ethanol. However, when the ethanol was added to the nanoparticles, the drug was
immediately released into the solution. However, we propose another option for in vitro
release profiling which utilizes proteins which transport estrogen in the serum. One such
protein is albumin. We propose to use a novel in vitro release study using dialysis with a
3% bovine serum albumin solution to transport the released estrogen. This setup should
yield a more reliable release rate than other methods because it mimics native
physiological conditions. This results in an in vitro approximation of the in vivo release
rate.
Nanoparticles loaded with estrogen will be placed in 300 kD dialysis bags and
will be analyzed for remaining estrogen at pre-determined time points. Estrogen release
will be determined using full loading as 100% of the loaded dose which was determined
in the loading yield section described later in the proposal. Amount remaining will be
determined using DMSO to dissolve the nanoparticle shell, releasing the estrogen into
solution. The estrogen content can then be assayed by absorbance using a
spectrophotometer at 285 nm, the absorbance spectrum peak for estrogens. To limit the
background the samples are purified using centrifugation at 7,500 RCF for 2 hours and
the supernatant is discarded. We then lyophilize the samples to remove the influence of
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dialysis volume change and to remove all water for re-suspension in organic solvent. We
plan to determine estrogen concentration at 0 hours, 24 hours, 48 hours, 72 hours, 5 days,
8 days and 12 days. This will illustrate the release profile of the drug from the
nanoparticle delivery system. This data will be used to determine the appropriate dose of
nanoparticles for the cell culture work in the following aims.
4.3.4.

Characterization of the drug loaded nanoparticle
4.3.4.1

Particle Size and Zeta-Potential

Particle size and zeta-potential were determined using dynamic light scattering
equipment (Beckman 90-Plus Particle Size Analyzer). The size data is shown as the
particle diameter of the size population with the largest number instead of a calculated
effective diameter which increases diameter by accounting for aggregates.
4.3.4.2

Nanoparticle 17β-Estradiol Loading Yield

Estrogen loading yield was determined using UV-Visible spectroscopy following
its absorbance at 285 nm. Nanoparticles were dissolved in dimethyl sulfoxide to release
17β-Estradiol and background absorbance of polymer and solvent were accounted for in
all calculations.
4.3.4.3.

Atomic Force Microscopy

Atomic force microscopy imaging was used to characterize the size and surface
characteristics of the nanoparticles produced. We determined the level of aggregation
using tapping mode in air. Nanoparticles were sonicated in a bath type sonicator and
diluted for AFM analysis. Dilutions were performed before a small drop is placed on a
mica substrate and allowed to dry before the AFM reading is taken.
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4.3.4.4

Freeze Drying and Long Term Storage

Lyophilization, or free drying, was performed to preserve the drug for storage and
prevent nanoparticle degradation during storage. Lyophilization was done according to
the following procedure. First, the sample to be freeze dried was frozen at -80°C for 2
hours. Following freezing, the samples were put into a flask for lyophilization. Small
holes were introduced into the vehicles carrying the samples (usually polypropylene
centrifuge tubes) before freezing to allow a vacuum inside the vehicle. The flask with the
samples was then attached to the freeze dryer and allowed to dry for at least 24 hours
before removal.
4.4.
4.4.1.

Results
Formulation Development of PEGylated PLGA Nanoparticles
The polymeric nanoparticles, constructed from PLGA and PEG-PLA, are

evaluated for their ability to encapsulate the drug to be loaded. The particles are separated
from unbound drug by centrifugation. This centrifugation is repeated three times to
ensure purification. The loading efficiency is analyzed by directly measuring the
absorbance of the drug which was encapsulated after dissolving the polymeric shell.
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Figure 14: Different poly(ethylene glycol) contents change the incorporation
efficiency of 17β-estradiol into the PLGA-PEG nanoparticles.
As can be seen from Figure 14, the highest loading efficiency obtained was over
50%. This data is also summarized in Table 1. There was a much lower loading
efficiency for the nanoparticles made with 25% PEG, is likely due to a decrease in the
amount of bulk polymer which can carry the hydrophobic drug. The 2.5% PEG sample
saw a similar loading efficiency to the 10%, but was slightly lower. The variable
measured here for determining loading efficiency was PEG content.
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Table 3: Formulation development for 17β-Estradiol nanoparticles coated
with PEG. Two different formulations were chosen to test for loading
efficiency. Loading efficiency is shown as a percent of original drug dose with
standard error.

Formulation

Loading Efficiency

Final Estradiol

PGA/PLA /PEG

Concentration

Concentration

(mg/mL)

(mg/mL)
11.875/ 12.5 /

2.5% PEG

46.2% +/- 5.9%

0.924
0.625

10% PEG

52.4% +/- 4.1%

1.050

10 / 12.5 / 2.5

25% PEG

25.9% +/- 2.4%

0.518

6.25 / 12.5 / 6.25

4.4.2.

Size Analysis of the Nanoparticles
The size of the developed particles is also important. Here, we show by DLS our

particles are approximately 50 nm and are generally monodisperse, or have a relatively
narrow distribution around the reported diameter (Figure 16). We also report the
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Figure 15: A bar graph representation of the relative number of
nanoparticles in different sizes. The majority of the particles are centered
around 50 nm, but there are some larger particles which are likely
aggregations of smaller particles.
zeta-potential to be highly negative which indicates stability of the particles and that there
will not be substantial aggregation. As can be seen in the DLS data shown in Figure 16,
the instrument does record particles with a larger size, but this is likely due to a small
degree of aggregation, which is lower here than in many nanoparticle formulations
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Figure 16: Atomic force microscopy image of the PLGA-PEG nanoparticles
loaded with estradiol. The bright white color indicates the highest points on
the image.
likely because of the PEG coating. The theory that larger particles are likely aggregates is
supported by our atomic force microscopy images of the particles. This image again
indicates that the particles do, in fact, have a small size distribution (Figure 18), but there
are some aggregates that can be seen in the larger scan. The size of approximately 60 nm
is also confirmed in Figure18. The small point on the top left of each nanoparticle is
likely due to a defect on the AFM tip which left the artifact seen in the image.
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Figure 17: The height (or diameter) of the nanoparticles can be discerned
from the AFM image. As can be seen at the top of the image, the size of the
nanoparticles is approximately 60 nm, with some small variation. The lighter
gray spots which are slightly larger than 5 nm are likely either locations
where previously attached nanoparticles were dislodged and left a residue, or
small areas of PEG-PLA on the charged mica substrate.
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ImageNote:
ImagingMode: AC Mode
ScanLines: 1024
ScanPoints: 1024
ScanRate: 0.10 Hz
ScanSize: 20.00 µm
Time: 7:57:54 PM

Figure 18: A larger scan of the nanoparticles. The majority of the particles
are of a narrow size range. There are a few larger particles that appear to be
aggregations of a few particles.
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Table 4: 17β-Estradiol nanoparticle and unloaded nanoparticle diameters
and zeta-potentials with error measurements from a particle size analyzer.
Particle size is given by the largest population of nanoparticles produced
with standard error. There is some variability, but this is not a major
concern. The strongly negative zeta potential measurements signal that the
particles are stable.
Nanoparticle
Zeta-Potential
Nanoparticle Type

Diameter*

Polydispersity
(mV)

(nm)
Estrogen
50 +/- 1.4

~0.194

-58.2 +/- 3.0

50 +/- 0.9

~0.080

-80.3 +/- 11.4

Nanoparticles
Control
Nanoparticles

*Major population of nanoparticles

4.4.3.

Release Profile Determination
We first analyzed the release of dexamethasone from PEGylated liposomes.

Liposomes are a popular drug delivery method because of their long circulation time and
resistance to body defense systems. DEX was released slowly from the carrier as can be
seen in Figure 19. The drug is slowly released over the first five days before a plateau is
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observed. There is some variability seen in the release profile, but it is apparent from the
profile that the drug undergoes a controlled release for the first several days.
Next, the method is shown capable of the elucidation of the in vitro release
profile in a polymeric nanoparticle system loaded with a different hydrophobic drug
(Figure 20). Here, we show that 17β-estradiol can also be transported by the protein.

Figure 19: Dexamethasone release from a PEGylated liposome using our in vitro
release profile which utilized albumin to transport the hydrophobic drug across a
semi-permeable dialysis membrane.
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Figure 20 shows a quick release over the first two days of the majority of the loaded drug.
This rapid release shows the ability for the rapid transport of the drug using this method.
We also performed the described dialysis based in vitro release determination method
without BSA to show that the albumin itself is playing an active role in transporting the
hydrophobic drugs across the semi-permeable membrane. Our results

Figure 20: The model drug, 17β-estradiol, loaded into polymeric nanoparticle
constructed from 50:50 PLGA is released quickly from the particles as they
degrade by hydrolysis. Estrogen release in the presence of albumin (Black
squares) is much higher than the release with only buffer (Red diamonds).
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indicate that there is almost no lost drug from the dialysis membrane, indicating that there
must be an active transport system to carry the drug across the membrane.
4.5.

Discussion
The lack of a good treatment for secondary events following spinal cord injury

necessitates the development of an effective treatment. The development of a particle
with high loading efficiency is vital to the future approval of the treatment for SCI. The
polymeric nanoparticles form when the dissolved polymer and drug solution is added
dropwise into an aqueous solution in which the polymer and drug are not soluble. An
input of energy from sonication allows the nanoparticles to form instead of larger
aggregations of polymer. In forming, the relatively hydrophobic polymer, PLGA in this
case, will form the core of the particle and encapsulate the hydrophobic drug, and the
PEG-PLA molecules will created a ‘solvent sphere’ of PEG on the outside of these
particles. The solvent sphere is formed because water molecules interact preferentially
with the hydrophobic PEG polymer. This hydrophilic layer around the particle diminishes
the thermodynamic propensity for proteins and molecules in the body to attach to the
particle and facilitate clearance. This PEG coating is anchored to the particle by the PLA
groups which have a preference for the PLGA core because of their common
hydrophobicity. The PEG plays the role of a surfactant in this case which functions to
stabilize the hydrophobic particle in aqueous suspension. Therefore, it stands to reason
that higher PEG ratios will result in smaller particles because there is more surface that
can be stabilized by the PLA-PEG. Thus, to determine the highest loading efficiency we
vary the PEG content. The results, shown in Figure 14, illustrate that the 10% PEG
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content increases the loading efficiency with the highest loading efficiency of above 50%
for the hormone drug in the mixture. This high loading efficiency is critical in keeping
production costs low, which is necessary for it to reach the market. There was a similar
loading yield in both the 2.5% PEG and the 10% PEG formulations, but in our results the
10% PEG was higher. Thus, for all future experiments the 10% PEG formulation was
used.
PLGA was chosen because it is an FDA approved polymer for drug delivery and
has been shown to have relatively little toxicity. Because the highest need for treatment is
immediately following injury and for the first few days following injury, a fast degrading
formulation of 50:50 PLA-PGA alternating co-polymer was used. If a need for a slower
release profile arises, this ratio can be adjusted as needed. There are no approved PLGA
nanoparticles as of yet, and there is a concern held by some that the nanoscale size of the
particles could be problematic.
As indicated, the size of nanoparticles is also critical to successful application as a
treatment for SCI. The size of 50-60 nm is consistent between both DLS and AFM
measurements of the size. The DLS measurements show a small number of a larger size
population. This could be larger particles in a weighted bimodal distribution, but is more
likely aggregation. The theory that there is a small degree of aggregation is corroborated
by the AFM data. The larger scan shows a large number of particles with a few larger
groups which appear to be aggregates of two to three nanoparticles. It is critical that there
are few aggregates so that the particles are capable of diffusion in the tissue, and so that a
consistent release rate is seen. These particles should not be in the circulation in large
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numberes, so clogging of the capillaries is not as much of an issue here as for intravenous
delivery, but limiting aggregation to prevent blockage of the lymph nodes, circulatory
system, or other locations is still appropriate.
The ability of the nanoparticle carrier to diffuse in the injured spinal tissue will
need to be determined in order to develop a treatment best suited for effective treatment
of SCI. Because the administration is local there is a need for a small enough particle to
allow some diffusion through the tissue to reach the entire injured region. In theory, large
particles in the range of microns will remain largely localized and release drug which will
be limited in its ability to diffuse in the tissue by its hydrophobicity. In addition, small
molecules, such as estrogens, can diffuse easily and potentially enter the bloodstream.
This is what we want to avoid in an attempt to treat only the local region and limit
systemic side effects.
On the other end of the scale, small nanoparticles which are less than 20 nm have
the potential to have high levels of diffusion and even potentially re-enter the
bloodstream, although the level to which this will occur is unknown at this stage of
treatment development. This can also be analyzed in future work if the therapy shows
efficacy.
This diameter of approximately 50 nm should be in the range of appropriate size
for local delivery and should allow for some diffusion through tissue, but the particles
will remain largely localized and able to treat the diseased site. It should also be able to
do all this without causing, or at the very least reducing, many of the side effects which
are typically associated with estrogen treatment. However, as the treatment is examined
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the nanoparticle may need to be adapted to the characteristics required by the disease.
This includes a possible adjustment in size as well as a possible change in polymer ratio,
or even a polymer change if it becomes necessary.
The in vitro release profile determination is an important characterization step
which aids in translation of the drug delivery system from in vitro testing to in vivo trials.
Elucidation of the release profile in the case of a hydrophobic drug is difficult for drugs
such as 17β-estradiol and dexamethosone as they are essentially insoluble in aqueous
media. Our analysis of the release profile of these drugs from their carriers can be used to
determine dosing over time or to tune the release profile for the specific need. This
analysis is typically done using ethanol as a solvent for polymeric delivery, but our
results (not shown) indicated complete loss of the incorporated drug immediately upon
suspension in ethanol. This is likely due to the compromise of polymeric integrity which
prematurely releases the drug. Liposomes are also compromised structurally by ethanol,
resulting in drug loss. Thus, we propose a new method of in vitro release profile analysis.
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Figure 21: Graphical representation of the in vitro release model utilized to
facilitate the release of estrogens from the nanoparticle carriers. The
estrogen (steroid chemical structure shown) is released from nanoparticles
(orange and grey spheres with PEG spikes), and is carried across the
membrane by albumin (BSA protein structure shown).
This method for assaying release of hydrophobic drugs from controlled release
modalities is tested using two drugs (17β-estradiol and dexamethasone) delivered by two
different PEGylated nano-sized delivery modalities (PLGA nanoparticle and liposome). It
does not require the use of harsh organic solvents and better resembles the in vivo release
rate due to transport proteins in physiological concentrations and an aqueous
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environment.In the body, 17β-estradiol and other steroids are carried by transport
proteins specifically designed to carry such hydrophobic molecules. We utilized one of
these proteins, albumin, to facilitate the transport of the drug and obtain a relevant in
vitro release profile. The actual degradation rate of the carriers should not be majorly
affected by the presence of protein. This method of release profile determination is
potentially more accurate at predicting the in vivo release profile because the transport
mechanisms are consistent. Our release profile showed a bolus release over the first few
days and then a slower release in the days following initial burst (Figure 20). A bolus
release just after administration could be advantageous to avert the initial damage which
can be catastrophic in the first few days following the injury. A lower release rate for the
days following should still play a therapeutic role, and, depending on the therapeutic
need, the lower concentrations are desirable in an effort to maximize the recovery with
limited side effects
We also performed the in vitro release determination method without BSA to
prove that the albumin itself is playing an active role in transporting the hydrophobic
drugs across the semi-permeable membrane. Our results indicate that there is little drug
lost from the particles without albumin present. This indicates that there must be
mechanism for transport facilitated by albumin to carry the drug across the membrane.
The release rate of the drug from the carriers should not be significantly altered by the
presence of BSA, so the drug is likely on the surface of the particles, or is precipitating in
the membrane compartment, thus preventing any useful release profile measurement.
Either phenomenon is not useful for in vitro evaluation because the limitation is not the
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drug release from the carrier, but rather the solubility of the drug in the surrounding
media. This solubility will be much higher in the body, when albumin and other transport
proteins are there to carry the drug.
The release of the drug over time illustrates the utility of this method over the
traditional method which, if it works at all, is not nearly as physiologically relevant. The
versatility of this method is also illustrated here by evaluating the release in another
model with a different drug. This ability of the albumin to carry a variety of different
hydrophobic drugs shows that this method can function for many different drugs. The
limitation here is that only molecules with naturally occurring transport systems can be
used. There are some molecules that could potentially be used because of their structural
similarity to the natural molecule. The versatility is also evident in the ability of the
method to reveal the release profile in a different drug delivery system other than the two
examined here (liposomes and PLGA nanoparticles). If the release profile is slower, the
method should still be able to reveal the profile, but this shows that if the release profile
is extended or rapid the method exhibits utility.
As stated, serum albumin has various physiological roles including the
transportation of hydrophobic molecules such as fatty acids, some vitamins, and bilirubin.
Albumin is being examined here for its ability to transport hydrophobic therapeutic drugs
and gives insight into the release rate of these drugs using an in vitro model, but there are
other proteins and other drugs to which this model may apply. Changes in temperature
can also affect the release rate of drugs from their carriers. As albumin is naturally stable
at physiological temperature and its melting temperature is measured at around 65°C, it
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should be able to be used at higher temperatures for accelerated release studies. This is
particularly useful for many drug release systems which release drugs over months or
years. This makes the translational in vitro analysis requested by the FDA much more
manageable.
Knowledge of the release profile early in the development process is useful to
researchers to adjust the release rate or dosing before translation into animal models. The
high cost of pre-clinical and clinical trials makes a reliable, physiologically relevant
release determination method an important asset to researchers in formulation
development for drug release systems for therapeutic application. This inexpensive,
physiologically relevant model for drug release uses a protein for drug transport just as
the drug would be transported in vivo, thus better mimicking the release dynamics. The
method described here is a much improved, reliable and useful method which should
translate well into animal models due to similar dynamics.
4.6.

Conclusions
We were able to successful incorporate 17β-estradiol into PEGylated PLGA

nanoparticles with a high efficiency. We analyzed the effect of PEG content on the
loading effiency and settled on a formulation using 10% PEG. The size of the
nanoparticles was also appropriate for initial studies into the efficacy of the proposed
treatment, and there was relatively little aggregation of the particles
Evaluation of the release profile is also an important step in the characterization
and analysis for in vivo efficacy. However, lack of solubility of hydrophobic drugs
prevents the accurate measure of the release profile in a physiologically relevant system.
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Thus, we have described a method to address this issue by using albumin, a transport
protein, to facilitate the transport of hydrophobic drugs across a semi-permeable
membrane. This system is useful not only because of the physiologically relevant protein
concentration and aqueous environment, but is also able to accurately measure the release
of drug even in the case of rapid drug release. It could also likely be applied as a model
for evaluated accelerated release with increased temperature so the release doesn’t have
to be performed in real time. We have shown this novel system is a useful tool in
determining the release rate of two model hydrophobic drugs for a diverse set of drug
carriers modeled here by PLGA nanoparticles and liposomes.
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CHAPTER FIVE
IN VITRO ANALYSIS OF THE ESTROGEN LOADED NANOPARTICLES IN A
NEUROBLASTOMA CELL MODEL
5.1.

Abstract
Spinal cord injury is a disease which can severely limit mobility and quality of

life. Currently, there is no good treatment for individuals with acute spinal cord injury as
the only treatment is highly controversial due to questions of efficacy. In the absence of a
good treatment option, 17β-esteradiol has garnered attention for its relevant therapeutic
abilities. However, the application of this estrogen is limited due to concerns of systemic
side effects. In answer to these concerns, we propose the incorporation of the hormone
drug into surface modified nanoparticles. These polymeric nanoparticles, which avoid
uptake in the body, will allow for a sustained release of therapeutic levels of drug over
time. This will limit the ability of the drug to reach distant tissues and cause deleterious
side effects as well as well as endow an extended therapeutic effect. The in vitro
evaluation of this system is performed here in a neuroblastoma cell model. We evaluate
this system for efficacy and show its efficacy in protecting the cells exposed to multiple
SCI-like events including glutamate excitotoxicity and oxidative stress.

5.2.

Introduction
Spinal cord injury is a debilitating condition which renders many with limited

mobility. There are about 12,000 new cases of spinal cord injury each year with 265,000
cases estimated in 2010 32. These injuries occur when a mechanical trauma to the spinal
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column causes a disruption of the structural integrity of the spinal cord and the
extracellular matrix is damaged as well as cell death. The injury stemming from the
mechanical force is referred to as primary injury. However, the damage continues to
progress for several days to weeks after the primary injury 43. This damage is caused by
biochemical cascades which are initiated when damage is caused to the spinal cord.
These biochemical events leading the more extensive damage are called secondary events
or secondary injury.
The effects of secondary injury include immediate effects from inflammation
which is partially characterized by the influx of microglia (macrophages of the central
nervous system) and neutrophils to up clean the site 38. These cells release reactive
oxygen species (ROS) which are also released due to ischemia/reperfusion injury which
is also characteristic of SCI 39. These ROS cause local oxidative damage to the tissue 39.
The compromise in the integrity of the blood brain barrier when an injury is sustained
causes an influx of glutamate into the spinal cord tissue 40 41. Glutamate is maintained in
the spinal cord, but in a lower concentration than in the rest of the body and the loss of a
barrier causes dangerously high levels of glutamate which lead to glutamate
excitotoxicity, triggering apoptosis 42.
The current treatment for acute SCI is methylprednisolone, which many doctors
consider to lack sufficient therapeutic efficacy to be used for SCI patients 41 46,50-52 1, 49.
This has led to research into other potential treatment options. One such option which has
garnered some attention is 17β-estradiol. This hormone has been shown to be involved in
several protective mechanisms which are relevant in SCI 37. This estrogen is an anti-
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inflammatory agent, an anti-oxidant, and an anti-apoptotic drug. Its anti-inflammatory
abilities come from its inhibition of microglial activation 65. It is an antioxidant, just as
many other steroids are antioxidants, although the exact mechanism is unknown 64.
Finally, it blocks glutamate receptors and prevents the downstream apoptosis triggered by
glutamate excitotoxicity 40, 41. However, despite the positive therapeutic ability that this
hormone has shown, there is significant concern over potential side effects, especially if
delivered systemically in high doses 6834. The primary side effect of concern is related to
the cardiovascular system , because estrogens can be prothrombogenic which is
especially problematic in a patient population with limited mobility often in the lower
limbs which are already prone to thrombosis 67. There is also concern that high dose
estrogens can be carcinogenic 69. There also more minor side effects which remain a
concern including gender related effects 70. Because of these effects there has been
investigation into the therapeutic effect of low dose estrogen. These experiments have
seen therapeutic efficacy even in low doses 34, 41. However, rapid clearance of the
hormone limits efficacy of free drug administered in low doses.
Nanotechnology offers a unique solution to the problem of systemic toxicity and
high doses. Nanoparticles can be used to carry the drug and slowly release it in
therapeutic levels at the site of injury 72. The larger size of the nanoparticles will prevent
the hormone drug from escaping the local injury in high quantities, potentially leading to
deleterious side effects. The sustained low levels of drug will constantly perform their
protective role to prevent further damage, but also will limit even the local adverse
effects. If administered without a carrier, the drug would be given in high doses because
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it is cleared so quickly that therapeutic efficacy dictates high doses or regular
administration, which can lower patient compliance. However, this is not necessary with
nanoparticle drug delivery.
Here, we propose the use of a PEGylated PLGA nanoparticle for the
encapsulation and sustained release of 17β-estradiol after local administration at the site
of spinal cord injury. PLGA is a FDA approved polymer which has been used extensively
as a drug delivery vehicle. This surface modification will allow for an extended lifetime
without clearance from the body, which will enable the controlled release and sustained
therapeutic levels of drug to the injured region.
5.3.

Research Methods

5.3.1. Materials
17β-estradiol, 50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw
7,000-17,000), and PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were
purchased from Sigma- Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) was
purchased from VWR (West Chester, PA). Bovine serum albumin was purchased from
SeraCare (Milford, MA ). DMSO, Chloroform, Acetone and other organic solvents were
purchased from VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro
(Manassas, VA).
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used for
specrophotometic analysis of an MTT-based cell proliferation assay and to analyze
steroid concentrations. Spectrum/Por Biotech Cellulose ester membranes with a 300,000
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kDa (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for
dialysis.
Nanoparticles were characterized by zeta potential measurements using a
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the
appropriate particle concentration. Data presented are the average of the measurements of
three separately prepared samples each analyzed in 5 runs.
5.3.2.

MTT Cell Proliferation Assay (Measure of cell viability)
Viability was determined using a MTT cell proliferation assay, which measures

the viability of cells. Briefly, (3-(4,5-Dimethylthiazol-2)-2,5-diphenyltetrazolium
bromide (MTT) was added to the wells after incubation with a challenge agent. This
MTT reagent was allowed to react with living cells for 4 hours to produce intracellular
purple formazan, which is insoluble in aqueous solutions. This crystal is dissolved, and
the reaction stopped, by adding a detergent to kill cells and solubilize the formazan.
Formazan levels were followed spectrophotometrically at 570 nm. Higher absorbance
values indicated a higher level of viability, or more cells alive in the corresponding well.
Background is removed from all readings before analysis was performed. Cell viability is
calculated by:

Statistical analysis of this study was performed using the student’s t-test. Error is shown
using standard error which is calculated according to:
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Where σ is standard deviation of the measurement and n is the number of repeats. Both
standard deviation and standard error are reported in Table 5.
5.3.3. Delivery of 17β-Estradiol for neuroprotection using DMSO as the vehicle
B35 Neuroblastoma cells were cultured using DMEM with 10% fetal bovine
serum (FBS) and 1% (50 units/mL) penicillin/streptomycin. Cell culture medium was
changed every 48 hours and cells were passaged before confluency was reached.
Neuroblastoma cells were seeded onto a 24 well plate and fed with 0.5 mL of media per
well. Three wells were not seeded with cells in order to have a background reading. After
cell seeding, the cells were incubated for 4 hours on the plate to allow for attachment, and
then the 24 hour incubation with the drug was started. Final concentration of DMSO in
the wells was 0.4% by volume. Both free estrogen and nanoparticle encapsulated drug
were administered to the neuroblastoma cells. The hormone drug, freed from the
nanoparticle, was used to verify that the preservation and encapsulation procedures did
not cause the 17β-Estradiol to lose its therapeutic abilities. 17β-Estradiol concentration
was in a final concentration of 37 μM in the treatment wells. Glutamate (17 mM) was
added 24 hours after drug treatment into the appropriate wells. A positive and a negative
control were used to illustrate the effect of the drug. The positive control contained only
neuroblastoma cells, media, and DMSO added in 4:1 PBS:DMSO solution, no glutamate
or drug treatment. This control showed the viability of cells without any addition, or
100% viability. The negative control contained glutamate and DMSO as added in the
positive control but no drug treatment. This control shows the effect of the glutamate
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with no neuroprotectant present. DMSO delivered free drug and DMSO dissolved
nanoparticle were prepared by dissolving the drug in DMSO and diluting the DMSO
four-fold with PBS. This solution was then added to the wells to be treated with drug.
5.3.4.

Delivery of 17β-Estradiol for neuroprotection using the nanoparticle construct

as the delivery vehicle
A similar method to that outlined for the delivery via DMSO is employed for
nanoparticle based delivery. Positive and negative controls are both used as described
previously, but with no DMSO. Estrogen loaded into the nanoparticle is also delivered at
a final concentration 37 μM but delivered in PBS alone for initial experiments but other
doses will be used in later dose dependent studies. Glutamate concentrations remain the
same and cell viability is calculated in the same manner after the reaction with MTT
reagent. DMSO controls were also run on the same plate to compare the effect of DMSO
on cell viability.
We will incubate the nanoparticle loaded with estrogen for 0 hours, 2 hours, 8
hours and 24 hours to determine the best pre-treatment time for increased viability of the
neuroblastoma cell line. A dose dependent response study will also be performed to
analyze the model’s response to different concentrations of the drug when delivered by
the nanoparticle vehicle. Several different concentrations will be used to determine the
optimal concentrations for effective neuroprotection.
5.4.

Results

Neuroprotective Efficacy of Estrogens Loaded into Nanoparticles
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17β-estradiol has been shown to have the ability to convey a neuroprotective
effect through several protective mechanisms. Because of the hydrophobicity of the drug,
the free estradiol is typically added via DMSO to cell culture model for evaluation of
efficacy. The DMSO is used to dissolve the drug and deliver it to the cells. To ensure that
the drug is still able to function in its protective role even after incorporation into
nanoparticles, we dissolve the nanoparticle shell in DMSO and compared the protective
ability to free estradiol also delivered via DMSO. As can be seen in Figure 6, both
treatments are able to protect the neuroblastoma cells with P < 0.05. Threre is a small
difference in viability that can be seen here, with a lower viability in the nanoparticle
treatment group, but there is no significant difference between the two drug treatment
groups.
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Figure 22: A significant improvement can be seen in the viability of both the
estradiol encapsulated into nanoparticles and the free estradiol. The polymer shell
was dissolved by DMSO and both treatments were identical except for the dissolved
polymer shell. This shows that incorporation into nanoparticles does not
significantly diminish the therapeutic ability of the drug.
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While performing these experiments, we noted that there appeared to be less
viability in the cells which were treated with DMSO. When explored further, we saw
only a small effect from DMSO alone with only a 3.5% drop in viability between positive
controls (Table 3). However, when the cells are treated by glutamate and DMSO, there is
a significant difference in the viability (Figure 7). When cells are treated with only
DMSO, there is not a significant difference between the DMSO treated and those not
exposed to DMSO (P ~ 0.1).

Figure 23: DMSO appears to be toxic to neuroblastoma cells when in
combination with glutamate. The effect appears to be present without
glutamate when the positive controls with DMSO were compared (P~0.1),
but not as significant as when glutamate and DMSO are combined (shown
above), giving a convincing statistical significance (P<0.0005).
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Table 5: Neuroprotection studies on estrogen loaded nanoparticles in a
neuroblastoma cell line. The challenging agent which estrogen protects
against is glutamate in this experiment.
In Vitro
Neuroblastoma

Standard

Number of

Error

repeats

42.25% +/- 3.16%

1.82%

N=3

40.07% +/- 3.49%

2.01%

N=3

33.85% +/- 3.51%

2.03%

N=3

96.58% +/- 1.40%

0.81%

N=3

67.41% +/- 7.49%

2.25%

N=9

55.55% +/- 5.51%

2.25%

N=6

100.00% +/- 2.67%

1.09%

N=6

Average Viable Cells (%)

Cell Treatment
DMSO Delivered
Nanoparticle
DMSO Delivered
Free Drug
DMSO Negative
Control
DMSO Positive
Control*
Nanoparticle
delivered drug
Negative Control
(No DMSO)
Positive Control
(No DMSO)
*DMSO Positive Control and other DMSO treatments compared to positive control (No
DMSO).
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However, when the cells are treated with glutamate and DMSO, the decrease in viability
compared to the control group only treated by glutamate is significantly different (P
<0.0005) (Figure 7). This indicates that DMSO is not the best delivery vehicle for the
drug, even in cell culture models, but certainly not for in vivo models in future
experiments.
There are several neuroprotective roles which 17β-estradiol can play following
SCI. Figure 24 shows the ability of the estrogenic nanoparticle to significantly protect a
neuroblastoma cell line from glutamate excitotoxicity. Estrogen was delivered in a total

Figure 24: 17β-estradiol loaded into nanoparticles is capable of significant
protection against a glutamate challenge in a neuroblastoma model.
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concentration of 37 μM and pre-incubated with the cells for 24 hours before glutamate
was added.
Dose dependence of the estradiol nanoparticles in a neuroblastoma cell model
As mentioned previously, the protective effect of 17β-estradiol is multifaceted.
Here, instead of glutamate, we will test the neuroprotective ability of estrogen against
oxidative stress. We will simulate this stress by introducing hydrogen peroxide in a 300
µM concentration to the neuroblastoma cells.
In an effort to determine the dosage which has the best ability to significantly
protect nervous tissue in the spinal cord, a study evaluating the protective effect with
varying doses was initiated. As can be seen from Figure 25, as the dose increases from
the low dose (37 nm), to medium (0.37 µM), to the high dose (37 µM), there is an
increased response. The lower two doses examined here are not significantly different
from the negative control, but the highest dose does see a significant protection. The
lowest concentration of estrogen shows a lower viability than the negative control, but
this is within the error and there is no significant difference between the two.

100

Figure 25: Dose dependence of the treatment of neuroblastoma cells with the
delivered estradiol on their viability after hydrogen peroxide challenge.
Doses used are as follows: low dose (37 nm), to medium (0.37 µM), to the
high dose (37 µM). All were pre-incubated for 24 hours.

Evaluation of pre-treatment times in a neuroblastoma model before challenge by
SCI-like event
Nanoparticles are used to deliver the drug to endow a controlled release of the
drug to the injured tissue. Thus, there will be a component of time in the effective therapy
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of SCI when this treatment regime is used. To evaluate the protective ability over time,
the nanoparticles are administed with different amounts of time before the challenging
agent, hydrogen peroxide to mimic oxidative stress following SCI in this case, is
administered to the cell culture. The pre-treatment times were 0, 2, 4, 8, and 24 hours.
As can be seen from the data in Figure 26, there is a general increase in
neuroprotection as more time elapses, allowing further degradation of the polymeric
carrier and release of the drug from the particle. There is a significant protective effect in
all treated samples, but the significance increases as the viability increases. The 8 hour
time point does experience what appears to be an anomalous decrease in viability.
However, there is no significant difference between the 8, 4, or 2 hour pre-treatment
times. Thus, while at 24 hours there is certainly the highest level of protection, the data
shown does not illustrate a difference in protection between the next three points (8,4,
and 2 hours) though they are all significantly improved over no treatment. The level of
significance does drop from P<0.001 for the highest three treatment times to P<0.005 for
the lowest two points. The 2h and 8h time points do appear to be similar, but the p-values
are different because of higher error in the 2h time point.
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Figure 26: Neuroblastoma cells are pretreated for varying amounts of time to
determine the neuroprotective effect at different time points. Estrogen was
used in a total concentration of 37 µM, but the time allowed for release from
the particles is varied.
5.5.

Discussion
In order to show that the proposed polymeric nanoparticle delivery system is

effective in treating secondary events, it is important to show protective efficacy in
models simulating these secondary events. First, the nanoparticle construct shows a
significant improvement over untreated cells when both are challenged by glutamate. It
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should be noted that glutamate concentrations were increased in this model due to a
limited response to normal physiological doses. This increase is likely necessary due to
resilience inherent to the malignant cell line which would not be present in normal in
vivo conditions. However, despite the increase in glutamate concentration, the treatment
does show a significant protective effect.
The effect is also seen for drug which was incorporated into nanoparticles and
free drug both delivered via DMSO. This effect illustrates that the incorporation process,
which includes dissolving the drug in acetone as well as sonication, does not compromise
the drug’s therapeutic abilities. It was observed was that DMSO was not an ideal drug
delivery vehicle as it did cause some toxicity when in combination with glutamate. Lack
of solubility in aqueous conditions prevent delivering 17β-estradiol in PBS or other
aqueous buffer, so for cell culture applications, DMSO has been used in the past. Current
estrogenic drugs are modified to increase their solubility in aqueous solutions and are
thus not subject to delivery via DMSO or other solvent.
The nanoparticle carrier, which shows an ability here to deliver the hydrophobic
drug in its native state, does offer an alternative to chemical modification or delivery
using a solvent medium. It is worth noting that the therapeutic effect of estrogens may not
be compromised by the addition of a sulfate group (which is the most common method of
increasing their solubility), but there may be a pathway towards approval and higher
efficacy for unmodified estrogens as well as for other drugs which have not been used
previously due to solubility issues.
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Initially, the neuroprotective effect was expected to be higher than was observed
in the lower two concentrations. Of course, the highest concentration, which was
substantially higher than would normally occur in the body, was expected to see the most
significant effect, unless there was a harmful effect caused by high the dose. However,
the more physiologically relevant doses in the nanomolar range (the two lower
concentrations) were expected to show a larger protective effect than was observed.
Other research showed that estrogen in the nanomolar range did show a protective effect
and if there was even 10% of the drug released in the 24 hour incubation time, the
medium dose would have been enough to surpass the 10-100 nM doses reported to be
neuroprotective in other studies 40, 217. However, it should be noted that the two
references studies used different cell cultures models which differed in estrogen
sensitivity by 10 fold. The cell model explored here also differs from both cell lines
reported in these studies.
This apparent lack of sensitivity to estrogens could be related to the cell culture
model, but could also be related to the high glutamate concentrations which were
required to see a response, but this is unlikely as the mode of action of estrogen functions
by limiting the response of glutamate receptors and not a direct interaction with
glutamate. Thus, an increase in glutamate should not necessitate an increase in estrogen
concentration. There is expected to be a release above 10% of the loaded dose based on
the release profile which was discussed earlier. This leads the researchers to one of two
conclusions. Either there is not as much drug released from the particles in cell culture
media as there was when the release profile was determined, or the neuroblastoma model
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used here (which is a different cell line than was used in other studies) is not nearly as
sensitive to estrogen as other cell lines. However, the DMSO delivered estrogen in the
glutamate SCI model was also delivered in this high estrogen concentration and a similar
effect was observed, which gives credence to the theory of insensitivity of the cell model.
Still, in the interest of determining the best dose for translation into an animal model,
both possibilities should be explored.
The pre-treatment time study shows that with more time allowed for the release of
the drug from the degrading particle, there is an increased protection of the cells from
oxidation and death. This trend is to be expected, but there does appear to be a protective
effect even when there is no pre-treatment time. This implies that either a small amount
of drug escapes immediately and plays a protective role, there is a protective role played
as the drug releases, or the likely case in which both occur to some degree. There is a
significant protective effect with these particles even when there is no pre-treatment time.
This is a good sign, as the patient needing treatment for SCI often times needs to receive
treatment as soon as possible. Current research indicates that treatment within the first 8
hours after injury shows the most significant improvement in patient outcomes. Thus, if
there was a long pre-treatment time necessary before any effect was seen, it could pose a
problem for the patients and the practical efficacy of the treatment.
The neuroblastoma cell in vitro experiments gives some useful insights into the
efficacy of the drug delivery system. However, as mentioned, there are some weaknesses
to this cell model. Neuroblastoma is a cancer cell line, which changes the dynamics of the
line compared with a normal healthy line. It is a resilient cell line that appears to be less
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sensitive than many other cell lines would be. When used in vivo, the cells would be
much more sensitive than the neuroblastoma line has proven to be. One example of the
reduced sensitivity is in the glutamate concentrations required for cell death to occur. The
concentrations required were in the milli-molar range, where in vivo the concentrations
which elucidate a deleterious effect are in the nano-molar range. There is also still some
question as to the cell line’s sensitivity to 17β-estradiol. Investigation into a more
relevant primary line is appropriate. Also, the difference between the treated cells and the
negative control are still small, and, though they are significant, a primary cell culture
model to show the same effect with greater significance is warranted.
5.6.

Conclusion
Overall, the treatment showed efficacy in our experiments in treating the

secondary effects associated with spinal cord injury. We showed that the treatment
resulted in significant improvement in cell viability both in glutamate induced toxicity
and in oxidative stress induced cell death. There was a dose dependent effect and
significance even with no pre-treatment time to allow for drug release from the
nanoparticle. Just as we have shown in vitro, the controlled release should result in
reduction to the damage caused in vivo by secondary events as well as acheive sustained
therapeutic levels of the drug. Due to what appears to be low sensitivity in the
neuroblastoma cell model, it is advisable to perform similar studies in a more
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physiologically relevant cell culture model before translation into an animal model.
Corroboration of the results here in such a model could provide the efficacy, dosing, and
pre-treatment information necessary to make a successful translation into in vivo small
animal studies to evaluate the efficacy of the nanoparticle estrogenic treatment.
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CHAPTER SIX
IN VITRO EVALUATION OF THE PROPOSED DELIVERY VEHICLE USING
A PRIMARY DORSAL ROOT GANGLION NEURON CELL CULTURE MODEL
6.1.

Abstract
Spinal Cord Injury (SCI) is a debilitating condition for many people, young and

old, which causes neurological damage and can result in paralysis. Acute SCI results in
an initial damage to the spinal cord, but secondary injury due to inflammation and
activated biochemical pathways leading to apoptosis exacerbate the injury. There are no
approved treatments for SCI, and the only available treatment is controversial218. 17βestradiol, an estrogen, is effective at ameliorating many of events involved in secondary
SCI including apoptosis. However, the therapeutic effect is limited by low retention time
of the drug at the affected location due to rapid clearance of the hormone. High doses and
regular administration are undesirable due to side effects, problems with patient
compliance, and a desire to limit discomfort. We propose to develop PEGylated
nanoparticles with estrogen loaded for treatment of SCI. Our hypothesis is that the
resistance to uptake, reduced immunogenicity, and controlled release endowed by the
nanocarrier will enhance the efficacy of the drug when compared with the undelivered
drug. Here we will evaluate the ability of the encapsulated estrogenic drug as a
neuroprotective treatment in primary cells isolated from a mouse spinal cord which are
used here to simulate spinal cord injury.
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6.2.

Introduction
Acute spinal cord injury is a condition which can result in significant motor

function loss and even paralysis. There are an estimated 12,000 new cases of spinal cord
injury each year and there were an estimated total of 265,000 people living with the
injury in 2010 32. The effect of the disease on these patients is widely varied and ranges
from almost no physical impairment to tetraplegia.
Cost of treatment varies with the severity of the injury. The estimated lifetime
costs for individuals of age 25 and 50 when afflicted with SCI are $1,461,255 and
$1,031,394, respectively, for incomplete motor function loss at any level32. The cost of
treatment for a 25 year old with paraplegia and tetraplegia ranges from $2,138,824 to
$4,373,912 for individuals with injury in the C1-C4 region of the spinal cord. Those with
tetraplegia in the lower section of the spinal cord see average lifetime costs of
$3,195,853. The average yearly costs for treatment of a patient with incomplete motor
function loss at any level is $321,720 for the first year and $39,077 per year after the first
year. Needless to say, this is a high cost to those who are plagued by this disease.
Spinal cord injury is caused by a mechanical trauma to the spinal cord resulting in
cell death and disruption of the extracellular matrix. Common causes of this type of
injury include vehicular accidents, falls, and sports related injuries, but are not limited to
these only. The mechanical damage can be severe, but is not the extent of the damage.
After the initial insult, there are biochemical events, referred to as secondary events,
which cause further damage to the region. These events include local increases in
neutrophils and microglia associated with inflammation 38, ischemia/reperfusion injury39,
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glutamate excitotoxicity caused by elevated glutamate levels after disruption of the blood
brain barrier 40, oxidative stress induced by several of the other mentioned events 38, ionic
imbalance 41, and activation of apoptosis and necrosis 42. These events start immediately
upon injury with the onset of inflammation and the arrival of microgia in minutes with
apoptosis and necrosis following in the first several days and followed finally by
revascularization and remodeling 43.
The current treatment for acute spinal cord injury, methylprednisolone, is
considered by many to be “an inappropriate standard of care” 1, 49. This serious allegation
stems from a series of clinical trials to evaluate the drug 46-48 which saw no evidence of
efficacy until a controversial post hoc analysis of the data was performed 46,50-52. These
questionable therapeutic effects lead medical professionals to search for other effective
treatment models 41. There have been other proposed treatments in the absence of a
universally recognized efficacious treatment. These include but are not limited to:
erythropoietin 61, 62 (which remains questionable because of a risk for thrombosis 63),
minocycline (which saw some positive results 57, 58, but a NIH study commissioned to
confirm the results was unable to reproduce the effect 60), and fullerenols (whose effect is
positive 54, but it remains in question largely because of its anonymity and a certain
degree of trepidation in the medical community towards unfamiliar and uncharacterized
technologies).
In the absence of a good, proven treatment model, research on the therapeutic
effects of estrogens, specifically 17β-estradiol, began to entertain the attention of the
medical community. Estrogens are familiar to the medical community and showed
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several therapeutic effects which are relevant to the deleterious effects following spinal
cord injury. These effects include an anti-oxidative action64, anti-inflammatory capability
65

, and, perhaps most importantly, anti-apoptotic ability 40, 41. In vivo models evaluating

the ability of the estrogens to prevent neurological damage have also demonstrated
neuroprotection 34, 37, 66. However, there are concerns for side effects including
thromboembolism 6834 especially in the lower limbs with an immobile patient population,
as well as gender related problems 70. Studies looking into therapeutic low doses which
limit the potential for side effects have been effective, but are limited by rapid clearance
of the hormone from the site of injury 34, 41.
In an effort to develop the most effective treatment for spinal cord injury, we
began an investigation into estrogen loaded nanoparticles for the local administration and
sustained release of the drug at the site of injury. Nanoparticles have been extensively
studied for their ability to endow a controlled release profile to a drug 72, 82, 97, 106, 206, 219.
Most of the nanoparticles which have been investigated for their therapeutic ability to
date have been for systemic delivery of the drugs 22, 30, 119, 220, 221. However, in this case
local drug delivery is more appropriate and will limit the side effects associated with
systemic administration of estrogens 168.

6.3.

Research Methods

6.3.1. Materials
17β-estradiol, 50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw
7,000-17,000), and PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were
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purchased from Sigma- Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) was
purchased from VWR (West Chester, PA). Bovine serum albumin was purchased from
SeraCare (Milford, MA ). DMSO, Chloroform, Acetone and other organic solvents were
purchased from VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro
(Manassas, VA).
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used
for specrophotometic analysis of an MTT-based cell proliferation assay and to analyze
steroid concentrations. Spectrum/Por Biotech Cellulose ester membranes with a 300,000
kDa (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for
dialysis.
Nanoparticles were characterized by zeta potential measurements using a
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the
appropriate particle concentration. Data presented are the average of the measurements of
three separately prepared samples each analyzed in 5 runs.
6.3.2. Primary dorsal root ganglion neuron cell culture model
Dorsal root ganglion neuron cultures were obtained from chicken embryos
between day 8 and 10 after fertilization. The collected cells were plated on collagencoated 24 well plates (40,000 –50,000 cells per well), and maintained in a CO2 incubator
in Dulbecco’s Modified Eagle’s Medium (DMEM) with L-glutamine, 4.5 g/L glucose, 50
units/mL penicillin/streptomycin, 10% fetal bovine serum (FBS), and 25 ng/mL nerve
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growth factor (NGF). DRG neurons are isolated by incubating the harvested culture for 4
hours and then collecting the cells which are not attached to the dish.
6.3.3. MTT cell proliferation assay for determination of neuroprotective efficacy in a
primary neuron cell culture model
The neuroprotective ability of the proposed estrogen delivery system will be
evaluated in a similar manner to that performed on the neuroblastoma cell model.
However, we will see a difference in the response as this is a different cell model which
will respond differently to the challenge as well as the treatment. Hydrogen peroxide
concentrations of 1.5 mM will be used to induce apoptosis in the cell culture model.
When delivered by nanoparticles, we will sustain the release of a therapeutic dose over
the first few days after injury, a time frame which has been shown to be critical. A
positive and a negative control were used to show efficacy. The positive control
contained only neuroblastoma cells and media, no glutamate or drug treatment. This
control shows100% viability and is the standard by which other viabilities will be
compared. The negative control contained hydrogen peroxide as a challenge but received
no drug treatment. Viability will be evaluated as previously described using the MTT cell
proliferation assay. Statistical analysis will be performed using the student’s t-test and
presented using standard error as described above.
6.3.4. Dosing determination in primary DRG neurons and the dependence of
neuroprotection on dose of the proposed estrogen loaded nanoparticle
We also determined the most effective dose for use in in vivo studies that will
continue the evaluation of the treatment regime. The dose was determined by
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administering hormone doses from the nano-molar range to the micro-molar range of
concentrations. The efficacy will be determined by cell viability using the MTT cell
proliferation assay after treatment. Low doses of estrogen have been shown to be
effective at ameliorating many of the effects seen in SCI. We plan to use the lowest
effective dose of the nanoparticle delivered drug. The total concentrations delivered in
the nanoparticles we will use are as follows: High (37μM), Medium (3.7 μM), Low (0.37
μM or 370 nM), and lowest (0.037 μM or 37 nM). However, sustained release of the
hormone over time results in a lower available dose at any specific time than would be
available if there was no controlled release. Thus, while the total dose is listed, only a
fraction of this is released per day. There is likely to be some variation in drug release
rate over time. The nanoparticle are designed such that there will be a bolus release when
first administered. This can be advantageous because higher doses are useful for
treatment immediately after injury, but sustained regional release at lower doses will
continue to protect the tissue in the region during the critical window after injury
6.3.5. Study on pre-treatment of cells with the nanoparticulate 17β-Estradiol and the
resulting efficacy.
The goal of the pre-treatment experiment is to limit the pre-treatment necessary
for efficacy as much as is possible. Wells seeded with our cell culture line will be
pretreated with the estrogenic nanoparticle to determine the best time for pre-treatment.
The ideal scenario is to not need any pre-treatment, as the drug would be effective
immediately upon exposure to the cells, but would also maintain therapeutic levels after
initial administration. We will vary the pre-treatment times with the maximum time of 24
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hours. We will look at the following pre-treatment times: 0 hours, 2 hours, 8 hours, and
24 hours. Pre-treatment efficacy will be evaluated using the MTT cell proliferation assay
to determine cell viability when exposed to the drug as described previously.
6.3.5. Study of treatment efficacy using different treatment windows with primary
cells as an in vitro model of spinal cord injury
The goal of the treatment window study is to evaluate the neuroprotective effect
of the estrogenic nanoparticle treatment regime after SCI like conditions are induced.
Wells seeded with our cell culture line will be treated with the estrogenic nanoparticle to
evaluate the treatment efficacy after challenge with hydrogen peroxide as described
previously. We will vary the times with a maximum window at 4 hours after treatment.
We will look at the following treatment window times after challenge: 0.25 hours, 1 hour,
and 4 hours. Treatment efficacy will be evaluated using the MTT cell proliferation assay
to determine cell viability when exposed to the drug as described previously.
6.4.

Results

Dose dependence in a primary dorsal root ganglion cell model
In the interest of obtaining evidence to corroborate the protective effect observed
in neuroblastoma cells, we use a primary cell culture consisting of embryonic chicken
dorsal root ganglion cells. The dose dependence shown in Figure 27 illustrates the effect
which the drug can have in protecting from secondary effects. In this case, oxidative
stress is modeled by using hydrogen peroxide to induce the stress which damages the
cells. Figure 9 shows that there is an increase in significance for the same dose when used
to treat the primary cell model when compared to the treatment of the neuroblastoma
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model. The significance of the neuroblastoma response (P < 0.01) was lower than that of
the primary cells (P = 0.0001). The response in the primary cells was such that a 10 fold
lower dose (3.7 µM) was evaluated and nearly reached significance (P = 0.053).
In this case, a higher dose of hydrogen peroxide was required to induce cell death.
However, the significance of the improvement is higher than in the neuroblastoma dose
dependence for the same treatment dose which was used in the neuroblastoma model. As
mentioned, in the high dose of estrogen applied to neuroblastoma cells there was a
significant improvement , but in the primary cell line with the same dose saw an even
higher level of significance. The lowest two doses shown are lower than the negative
control, just as was observed for the lowest dose in the neuroblastoma line, but again, this
is within the error of the measurements and there is not a significant difference between
them. While the range of doses did not change between models, the response appears to
be more significant in the primary cell line.
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Figure 27: Dose dependence of primary DRG neurons when treated with
varying concentrations of our estrogen drug delivered by PLGA
nanoparticles.
Pre-treatment of the primary cell culture model to evaluate efficacy
We also performed a study of the effect of pre-treatment time on the
neuroprotection of the treatment, just as was done with the neuroblastoma model
previously. Here we show a trend which generally decreases with the time allowed for
the polymeric shell to degrade. There is a very high level of protection in the 24 hour pretreatment. The viability is almost up to the level of the positive control, which did not see
hydrogen peroxide as a challenging agent. The significance for this highest point (P <
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0.0005), is lower than the P-values we saw for the neuroblastoma model and, again, the
treatment efficacy shows a higher level of significance in the primary line than in the
neuroblastoma line. This is good news as the primary line should be more indicative of
the in vivo response. The other three treatment times also showed significant
improvements over the untreated negative control as well. The 0h time point does diverge
from the expected trend as the viability increases to a higher level than was seen the 2h
treatment. However, there is no significant difference between the two, despite a modest
increase in the significance of the 0h treatment over the 2h when both are compared to
the untreated control.
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Figure 28: Pre-treatment of primary neurons with the polymeric
nanoparticle to protect against oxidative stress induced to simulate SCI.
Treatment window study in a primary cell model
A treatment window study to evaluate the efficacy of the treatment method was
performed using hydrogen peroxide as the challenge agent. The treatment was added at
three time points following the addition of the challenge agent which was added to
simulate SCI injury. This study gives insight into the ability of the treatment to play a
neuroprotective role even when used after injury, as would be the case in the clinic. The
results (figure 12), show significant neuroprotection at 0.25 hours after the SCI
conditions are induced, with decreasing viability in the following time points. When the
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pre-treatment and treatment window studies are combined to give a complete picture of
the response to treatment, a trend emerges which shows a decreasing viability with time.
This trend is expected, and can be clearly seen in figure 13. Cell death occurs rapidly
upon the addition of the challenging agent in the cell culture models, but the
physiological response to spinal cord injury leading to cell death is much slower. This
physiological response is extended to several days following the initial insult.

Figure 29: Estrogen loaded nanoparticles in 37 µM concentration incubated
with primary DRG neurons 0.25 h, 1h, and 4h after a 24h challenge with
hydrogen peroxide show a neuroprotective effect only in the earliest
treatment time. (n=3)
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Figure 30: Combination of the treatment time data illustrates the trend of
increasing viability with increased drug release time allowed. Drug was
delivered in 37 µM concentration.
6.5.

Discussion
The observed response sheds light on the potential therapeutic effect that this

treatment could have on a patient population without a good treatment option. The
primary cell culture model was primarily examined for two reasons. First, we want to
show that the treatment was effective in multiple SCI cell culture models including a
primary cell model which would likely be more sensitive to the hormone drug. This
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model was chosen because it will provide a more physiologically relevant model that
should aid in the translation of the treatment from in vitro to in vivo in small animal
studies. Second, even though significance was achieved in the neuroblastoma model, the
model was resilient and the significance was not as high as we believed it would be in a
more relevant model. Also, the appearance of a lack of sensitivity to low estrogen
concentrations gave credence to a further examination of the efficacy in a more relevant
cell culture model.
While efforts will be made to ensure a mostly pure line of primary dorsal root
ganglion cells, there will be a small degree of other spinal cord cells present including
glial cells. This will only better mimic the response that should be expected in vivo
because the in vivo environment will most certainly contain a variety of cell types
arranged in the spinal column.
One of the expectations in using a primary cell model was that it would be more
sensitive to estrogen than the neuroblastoma model appeared to be. However, the same
high concentration of estrogen was required here to see significance. There was a higher
level of significance, but a new intermediate concentration which is 10-fold lower than
the high concentration narrowly missed significance. This implies that there was a higher
level of sensitivity to estrogen in this model as a significance of P < 0.01 was seen for the
highest concentration in the neuroblastoma model and the level of significance here for
the same concentration was much lower at P < 0.0001. Despite the inability of the lower
concentration to reach significance, it does appear that this model is more sensitive, as the
level of significance of the 10 fold lower concentration approached significance (P =
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0.053) and the significance in the neuroblastoma model was only modestly lower, but
notably significant (P < 0.01). Still, the model does not reach the level of sensitivity tio
estrogen in low concentrations that was seen in other cell culture models 40, 222.
The lowest concentrations not reaching significance raises questions as to why
this did not occur. The possibility does exist that it is related to the cell culture model, as
it appears that the primary model is more sensitive to estrogen than the neuroblastoma
line. In the referenced studies which saw significance in neuroprotection even at nanomolar range doses, DMSO was used as a delivery vehicle. It could be that a decreased
solubility of the estrogen in the cell culture medium compared with DMSO slowed the
release from nanoparticles or otherwise limited availability of the drug. This reduction in
available estrogen could account for a change in the response of the cell lines. If this is
the issue, the presence of albumin along with other proteins which actively transport
hydrophobic molecules such as estrogens in the body will increase the release rate in vivo
and could result in a more dramatic neuroprotective effect, or an similar effect with a
much lower dose.
In the pre-treatment study, the fact that there is a significant protective effect even
in the lowest example of viability is encouraging. The early treatment of spinal cord
injury has been shown to be critical in effective treatment. So the significant
improvement even with no incubation time shows that this treatment could immediately
begin ameliorating the effects of secondary spinal cord injury. What is more encouraging
is that 48 hours after administration of the drug (24 hour pre-treatment time followed by a
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24 hour incubation with hydrogen peroxide) there is significant improvement almost to
the level of complete viability in the pre-treatment study.
Of course, administration of the treatment before the simulated secondary events
begin is not a scenario that is relevant to the clinical treatment of SCI patients. However,
it does give insight into the therapeutic ability of the treatment model. The treatment
window study does show evidence of treatment efficacy after injury conditions are
present. This indicates that the treatment will play a neuroprotective role even when
administered while the secondary effects are causing further damage to the region. It is
important to note here that while cell death occurs within the first few hours after
secondary conditions are induced in vitro, this process is much slower in vivo, taking
several days to cause such high level injury. We expect that the treatment will be
effective in preventing cell death in vivo due to the larger therapeutic window in vivo.
This indicates that our increasing therapeutic efficacy in vitro, showing the highest
measured level of efficacy at 24 hours after treatment, should be effective in treating
secondary injury both early as indicated in the therapeutic window study, and extending
for at least 24 hours after administration. If this treatment system continues to show
efficacy, future studies will allow for further evaluation in animal models with induced
spinal cord injuries.
The significance of the high doses is noteworthy and indicates the potent ability
of the evaluated drug to effectively prevent some of the secondary damage after SCI. The
outcomes here illustrate the efficacy of the system and support the further evaluation of
the system. Studies in animal models of spinal cord injury to continue the treatment
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evaluation are warranted after the in vitro success demonstrated here in a primary cell
culture model.
6.6.

Conclusion
In summary, the nanoparticle based estrogen delivery system shows efficacy in

the primary cell line examined here. This effect was more significant that was seen in the
neuroblastoma model. The higher level of physiological relevance of the primary
response gives credence to the continued evaluation of this treatment as a good option for
treatment of acute SCI. This also implies that the treatment model should have a more
pronounced effect in an in vivo model than would be expected from only seeing the
neuroblastoma outcomes. While there are still questions to be answered, at this stage,
evaluation of the proposed treatment is warranted in a small animal in vivo model. This
will shed more light on the potential of the system to effectively treat SCI in the future.
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CHAPTER SEVEN
CONCLUSIONS AND FUTURE RECOMMENDATIONS
7.1 Conclusions
Overall, the incorporation of estradiol into nanoparticles for the local, sustained
delivery of the drug to prevent the secondary effects following spinal cord injury was
successful in our in vitro experiments. Our goals were threefold in approaching the
development of an effective treatment modality. First, we developed an effective formula
for high encapsulation and then characterized the construct. Second, we evaluated the
neuroprotective efficacy, dose dependence, and the effect of pre-treatment time in a
neuroblastoma model. However, the resilience of the cell line necessitated another model.
Thus, our final goal was to analyze the therapeutic efficacy of the developed drug
delivery system. The combination of these three goals paves the way for translation into
an animal model study to further evaluate the treatment.
The first goal leads to several conclusions. First, we achieved a high
incorporation efficiency of the drug into the particle population. This high loading yield
makes the proposed delivery system a feasible option for treatment. If the loading
efficiency were low, then the cost to produce the treatment would be higher. Also,
perhaps more importantly, there would have to be a larger dose of nanoparticle
administered to the patient to see the same response. This would limit the successful
application as increased doses could lead to increased inflammation due to acid
degradation products from the biodegradable polymers. There has not been a strong
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enough inflammatory response to limit the application of other PLGA delivery systems,
but limiting the dose of polymer is appropriate nonetheless.
Second, we analyzed the size by DLS and AFM and saw that the size was
appropriate for local delivery over a several day therapeutic window following the
primary injury. With a size of approximately 50-60 nm, they fall in a narrow window of
size where a useful effect should be able to be achieved. Very small particles could see
two barriers for our application in vivo which could limit their efficacy. Small particles
are usually associated with renal clearance which would be limited because these
particles are administered locally. Although this is not a major issue, there are other
issues. Small particles would have a limited load which they could carry. Also, small
particles are much more capable of diffusion within the tissue, which could allow the
drug to spread outside of the region of interest. Larger particles can also negatively affect
the diffusive ability of the treatment. Since the treatment is to be administered locally,
there must be some ability of the treatment to spread through the injury to treat the entire
region. If the particles are too large, there will be a limited ability to do this. Again, the
typical limitation in size of particles is due to clearance, but this time on the larger scale.
The liver clears out larger particles, but this barrier is avoided by local delivery of the
drug. If intravenous administration was used, even if the particles small enough to avoid
rapid complete clearance, a large fraction would still be removed before any functional
role could be realized.
The release profile in which we utilized albumin as a transport vehicle for the
drug showed the desired initial bolus release with a slower release after the first two days.
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As discussed in the literature review, the majority of the deleterious effects following
spinal cord injury occur within the first few days. Thus, the release profile appears to be
tuned to the needs dictated by the pathology of the disease. However, if a need surfaces
requiring an adaptation of the profile to a slower release rate so as to provide a protective
effect for longer after the injury, this could be easily performed. This current profile
should be able to effectively limit the immediate negative effects following injury in the
first few days, and limit the response in the week or two following.
The in vitro release method also has other applications. Our results only show two
possible drugs for which this method can be applied. However, there are a wide variety of
drugs that are carried by albumin in the body, and if another protein is used, it opens up
the application to encompass almost any biologically relevant hydrophobic molecule.
This, in combination with the thermal stability of albumin and many other proteins at
elevated temperatures, could provide a good system for measuring the release of drugs in
an accelerated fashion by using higher temperatures. In addition to these advantages, it
also likely provides a more accurate release profile to that which will be seen in vivo
because the environment is similar. Many of the major components, including the
aqueous ionic buffer, temperature, and transport proteins are present. Apparently, there
are many other factors which affect release in vivo, but this model provides one more
variable in common with in vivo release.
The in vitro models are able to give further insight into the efficacy of the
treatment. The neuroblastoma in vitro model shows that estrogen delivery by DMSO
causes toxicity when combined with glutamate. However, estrogen delivered by
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nanoparticles shows an ability to protect against the damage caused by glutamate
excitotoxicity and against oxidative stress induced by hydrogen peroxide. These
neuroprotective effects, in combination with the anti-inflammatory capabilities of
estrogens, illustrate that this is a treatment with potential for high levels of therapeutic
efficacy.
The dose dependence showed that a high total dose of 17β-estradiol was required
to see a significant protective effect. However, the amount of drug released in the 24 hour
incubation time is likely much less than the total amount of the hormone which was
loaded into the particles. The release study described in chapter 4 does give insight into
the amount of drug which would likely be released, but could be more closely correlated
to in vivo release than what would be seen in an in vitro model. Despite some questions
which remain, the study did exhibit neuroprotective efficacy against both oxidative stress
and glutamate excitotoxicity.
There was a significant protection noted in all time points of the pre-treatment
time study. The level of protection did increase as more time was allowed for the drug to
release, but even with no pre-incubation there was significant protection. This is
important as the treatment is translated to in vivo models because the drug will be more
effective if it plays a protective role immediately upon administration.
The overall conclusion of the in vitro study with neuroblastoma cells was that
there was a need for corroboration of the data obtained from a more relevant cell culture
model. It is necessary to confirm this data in order to effectively translate this treatment
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into an animal model for further evaluation. Thus, further in vitro analysis was to be
performed in a primary neuronal cell model.
A primary dorsal root ganglion culture was used to continue evaluation of the
treatment. The dose dependent study confirmed the findings of the neuroblastoma model
that the treatment is significantly protective against oxidative stress. The dose required
for significance was consistent between the two cell culture models, but there was higher
significance in the primary model, which should have more relevance to an in vivo study
than the neuroblastoma model. This higher level of significance gives credence to the
theory that the model should be effective in treating the secondary effects following
spinal cord injury in vivo.
The primary pre-treatment study saw a similar increase in significance over the
neuroblastoma experiment. In this case the cells which were treated by nanoparticle
delivered hormone were almost unaffected by the induced oxidative stress. This can be
seen in that the viability was just below that of the positive control, which was not subject
to the oxidative challenge. Again, significance was seen in all pre-treatment times which
confirmed the data observed in the neuroblastoma model. The treatment window study
showed that the treatment is significantly effective in the primary cell model even 15
minutes after the secondary effects were induced. The combination of the pre-treatment
and the treatment window study show a trend of increasing viability as more time for
release is allowed. This is important because the therapeutic window for treatment is over
several days following injury, so the high viability observed at 24 hours before the
induction of injury conditions is still relevant. While it only takes an hour for extensive
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cell death in the vitro conditions the time frame in vivo is much longer. This allows for a
more effective treatment with neuroprotection for several days.
Overall, the conclusions made from the in vitro study with neuroblastoma cells
were confirmed in the primary cell culture. There was a protective effect exhibited in
both cases, but the more clinically relevant primary model was more protected by the
drug and saw a more significant improvement than those that were not treated. The pretreatment studies also illustrated that the primary cell model was more responsive to
treatment with higher viability levels after treatment. Another consistent observation was
that all time points for the pre-treatment study showed significant neuroprotection. This
indicates an immediate therapeutic role being played by the nanoparticle treatment.
7.2 Future Directions
While there has been evidence of treatment efficacy shown herein, there is still
much work to be done. First, more experiments remain to prove further efficacy of this
treatment system. There could also be an expansion of the treatment to more disesase
models. Combination of this treatment with other therapies to produce the most effective
disease treatments is another future direction. Here we will outline some of the future
work to continue development, modification, and studies to show efficacy of the
developed controlled release formulation for 17β-estradiol therapy.
One of the first experiments which should be performed is an analysis of the
estrogen concentration in cell culture medium. There was some question of release rate in
cell culture medium due to a lower response to estrogens in low concentration than was
expected. An ELISA which accurately measures serum 17β-estradiol can be used to
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evaluate this release in vitro. This data can also be compared to the in vitro release
described in this document, and to a potential future study which could examine drug
concentration and release in vivo. Our collaborators at the Medical University of South
Carolina will evaluate the release of estrogens in vitro in a cell culture using an estradiol
ELISA kit.
There are many applications of the method proposed here for the release profile
determination of hydrophobic drugs. This could be especially useful if accelerated aging
with the system is demonstrated as a potential application of the system. One path of
future research examines this possibility and would explore the effect of increased
temperature to accelerate the degradation of polymers and the release of drugs. With
some polymeric drug delivery systems taking several months to release their load, an
accelerated aging system would decrease the time necessary to analyze release.
Another potential study would determine the ability of the nanoparticles to diffuse
in the spinal cord tissue. This would be a useful experiment as the diffusion of these
particles is helpful if it is only a small degree of diffusion, but could lead to problems if
the diffusion is extensive. It is also important to show that the particles are not able to get
into the circulation and be carried everywhere in the body. This study could be performed
using fluorescently labeled nanoparticles administered in a small animal model through
local administration while following fluorescence through in vivo monitoring. The
monitoring could be performed using an IVIS Lumina XR in vivo imaging system.
The ultimate goal for this study is to translate the formulation into a viable drug
candidate that effectively treats spinal cord injury. To achieve this goal, there are several
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steps to be taken. First, a few more characterization steps will be carried out to determine
treatment dosing and administration time, some of which have already been mentioned..
These experiments will serve to confirm the experiments performed here. Our
collaborators at MUSC will use an organotypic model using a sectioned rat spinal cord to
determine the treatment efficacy in vitro with all the cells and matrix in its native
arrangement. This study should lead to effective translation into an animal model to study
the proposed drug.
A rat model will be used to analyze the drug’s efficacy. A spinal cord injury
model using a defined weight dropped from a consistent height onto the exposed spinal
cord will mimic the spinal cord injury and the treatment will be directly applied at the
injury site. If the rat study is completed with success and improvements in motor
functions are seen as well as other benchmark outcomes, then a small scale human trial
will commence. The scale of the clinical trials will increase until FDA approval is
achieved or if the drug proves to be unsafe or lack sufficient efficacy to continue.
Future work will also include further characterization of the particle make-up. The
composition of the particles will be analyzed including the evaluation of the drug and
polymeric components and their distribution in the particles. This is an important factor
in determining how the body will respond to the therapeutic treatment. It also will add
insight into the material which will aid in explaining and predicting the degradation and
release profile, as well as the physiological response and biodistribution.
Another area of research which could improve the therapeutic efficacy of the
proposed system is the addition of another therapeutic drug to work in tandem with 17β-
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estradiol. As mentioned, there are many pathways which cause damage after SCI, and the
solution may be in one drug that plays several therapeutic roles, or in a combination of
drugs. Estrogens do function in several protective roles, but the addition of other drugs
which can, for example, stimulate axonal regeneration would be advantageous. Other
therapeutic drugs could also be explored.
Also, the first several weeks after the injury could be treated by the proposed
system, and then a biomaterial system with stem cells and cytokines to stimulate
regeneration could be utilized. Such a system has been explored by the group led by Dr.
Sakiyama-Elbert 223, 224. This work focuses on repairing the spinal cord using controlled
release of chemical factors which stimulate growth and recovery 225-227 in combination
with the seeding of new cells 228, 229 and the formulation of a structure which promotes
ingrowth 226, 230. The combination of such therapies could be the most effective treatment
to repair the damage caused by SCI.
Another potential long-term application of this technology, if it sees success in
this application, is in the treatment of other diseases. The PLGA nanoparticle loaded with
estrogen for delivery could be potentially effective at treating other diseases. Estrogens
are thought to be involved in the pathology of several diseases, especially those which are
related to the nervous system. Parkinson’s disease, Alzheimer’s disease, and multiple
sclerosis are diseases which estrogen may have therapeutic potential. If estrogen is shown
to be involved in the biochemical pathways related to these diseases, then the
neuroprotective role of estrogens could be useful for therapeutic application.
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For example, some experts believe that estrogens play a role in the development
of Parkinson’s disease. This thought stems from the fact that many populations at risk for
Parkinson’s have a low or lessened estrogenic production level 11. However, this
hormonal involvement in the pathology of Parkinson’s disease is contested 11. If estrogen
treatment of spinal cord injury proves to have a therapeutic effect, there are other
potential paths for successful treatment of other diseases with limited side effects.
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Appendix A: Abbreviations
AFM – Atomic force microcopy

NASCIS –National Acute Spinal Cord

BCNU -1,3-bis (2-chloroethyl)-1-

Injury Study

nitrosourea

NMDA – N-methyl-D-aspartic acid

BSA – Bovine serum albumin

PBS – Phosphate buffered saline

CNS – Central nervous system

PEG – Poly (ethylene glycol)

DLS – Dynamic light scattering

PEG-PLA – Poly (ethylene glycol

DMEM – Dulbecco’s Modified Eagles

(block)-co-polylactic acid (block))

Medium

PGA – Poly (glycolic acid)

DMSO – Dimtheyl sulfoxide

PLA – Poly (lactic acid)

DRG – Dorsal root ganglion

PLGA – Poly (lactic-co-glycolic acid)

EPR – Enhanced permeation and

RES – Reticuloendothelial System

retention

ROS – Reactive Oxygen Species

FDA – Food and Drug Administration of

SCI – Spinal cord Inury

the United States government

SPARC - Secreted protein, acidic and

IVIVC – In vitro in vivo correlation

rich in cysteine

MP – Methylprednisolone

TEM – Transmission electron

MTT - (3-(4, 5-dimethylthiazolyl-2)-2,

microscope

5-diphenyltetrazolium bromide)

138

Appendix B: AFM Calibration and Supplemental Images

Figure 31: Screenshot showing the consistent fit of the thermal graph and other
details before AFM imaging was performed.

TuneGraph

Figure 32: AFM tune graph done before the readings on the nanoparticle size.
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Figure 33: Screenshot showing the details of the 20µM scan of the nanoparticles.
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Figure 34: Evaluation of the size of the measured nanoparticles in a 3µM scan.
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Figure 35: Height determination in the 3µM scan
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Figure 36: Height analysis of the small residue on the substrate. The leading
thought is that this is residue of PEG from once attached nanoparticles which
were blown off or rolled to a new location.
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Appendix C: DLS Supplemental Images

Figure 37: DLS screenshot which shows a high number of particles centered around
50 nm, but with a small group of larger particles. The effective diameter is much
larger than the bars would indicate, but the value is affected more heavily by
intensity than number (see next Figure)
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Figure 38: DLS image showing the high intensity of the larger particles. The laser
scattering is much more intensified with the large particles (which are likely
aggregates), and thus the effective diameter which program computes is weighted
towards larger particles.
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Figure 39: Correlation function of the reading on estrogen nanoparticles from the
DLS. This correlation function fits the approximate shape appropriate for accurate
reading function.
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